| ¬ÛÃöÂå¾Çºô |

¥xÆWªº«aª¬°Ê¯ß¤ßŦ¯f
«aª¬°Ê¯ß¤ßŦ¯f¬ã¨s¤p²Õ
¬y¦æ¯f¾Ç¡@¯f¦]¾Ç¡@Á{§Éªí²{¤Î¹êÅç«ÇÀˬd¡@¹w«á¤Î¤º¬ìªvÀø¡@°Ñ¦Ò¤åÄm
¦æ¬F°|½Ã¥Í¸p¤K¤Q¤@¦~«×©e°U¬ã¨s­pµe¬ã¨s³ø§i
­p¹º½s¸¹¡G¢Ò¢Ý¢Ö
­pµe¦WºÙ¡]¤¤¤å¡^¡G¥»¤gÂå¾Ç¸ê®Æ®w¤§«Ø¥ß¤Î½Ã¥Í¬Fµ¦¤W¤§À³¥Î
¡@¡@¡@¡@¡]­^¤å¡^¡GThe Establishment of Data Bank for Domestic Medicine and Its Application
¡@¡@¡@¡@¡@¡@¡@¡@¡@in Health Policy
°õ¦æ¾÷ºc¡G¤¤µØ¥Á°ê¥xÆWÂå¾Ç·|
°õ¦æ´Á­­¡G

¬y¦æ¯f¾Ç
¼Æ¤Q¦~¨Ó¥xÆWªÀ·|ÅܾE¬Æ¼@¡A¸gÀ٬𭸲r¶i¡A¤wªñÁÚ¤J¤w¶}µo°ê®a¤§ªL¡C°£¤F¥Ñ¹A·~ªÀ·|¨B¤J¤u·~®É¥N¤£¥iÁ×§Kªº©Ò¿×sedantarylifeªº¼W¥[¥~¡AÀHµÛ¥Í¬¡¤§´I¸Î¤Î³Á·í³Òµ¥³t­¹©±ªº¤J«I¡A°ê¤Hªº¶¼­¹²ßºD¤wº¥ÁͦV¦p¼Ú¬üªº°ª¼ö¶q¡B°ªÁx©T¾J«¬ºA¡C¦Ó°ª¦åÀ£¨¾ªv¤Î¸T·Ï«Å¾Éµ¥ªñ¦~Áö¤w¨ü¨ì¬F©²ªº¬Û·í­«µø¡A¦ý¦¨®Ä«h¥¼ª¾¡CÁöµM¦³Ãö«aª¬°Ê¯ß¤ßŦ¯f²±¦æ²v¤§¥¿¦¡¤åÄm³ø§i¤£¦h¡A¦ý¦U¤jÂå°|ªºÁ{§ÉÂå®v¬ÒÆ[¹î¨ì¤F«aª¬°Ê¯ß¤ßŦ¯f¯f¨Ò¤§ÅãµÛ¼W¥[¡A¥B¦~ÄÖ¦ü¥G¥ç¦³¤U­°¤§ÁͶաCªñ¨â¦~½Ã¥Í¸p»P¥x¤jÂå°|§õ·½¼w±Ð±Â¦X§@¤§ª÷¤sªÀ°Ï¤ßŦ¦åºÞ¯e¯f¬ã¨s­p¹º¥Ø«e¤w¦¬¶°¤£¤Ö¬ÛÃöªº¬y¦æ¯f¾Ç¸ê®Æ¡A¬Û«H«Ü§Ö·|¦³³Ìªñªº¤åÄm³ø§i¡C¦¹®Éµ§ªÌ¶È¯à´N¤w¦¬¶°¨ìªº¦³­­¸ê®Æ¥[¥H¾ã²z¡A²¨º|¦b©ÒÃø§K¡A©|½Ð¥ý¶i¤£§[«ü¥¿¡C

¾Ú¥x¤jÂå°|1957¦~1¤ë¦Ü1962¦~3¤ë¤§¤º¬ì¦í°|¯f¨Ò¦@1554¤H©Ò°µ¤§²Î­p¡A¤ßŦ¦åºÞ¯e¯f¦û31.3¢H¡A¦Ó¨ä¤¤¤ßµ±µh¤Î¤ß¦Ù±ð¶ë¶È¥e©Ò¦³¤ßŦ¦åºÞ¯e¯f¤§11.4¢H¡A¦¸©ó°ª¦åÀ£¤Î°ª¦åÀ£©Ê¤ßŦ¯f¤§66.3¢H¤Î­·Àã©Ê¤ßŦ¯f¤§11.6¢H¡A¦W¦C²Ä¤T[1]¡C¦Ó¤T¤Q¦~«áªº¤µ¤Ñ¡A¬Û«Hª¬ªp¤w¤j¦³§ïÅÜ¡A±¤¥¼¨£ªñ¦~¤§³ø§i¡C

¦Ü©ó¦bªÀ°Ï¤§ª¬ªp¡A®Ú¾Ú1965¦~6¤ë¦bÃú®p©Ò°µªº¬ã¨s¡A©ó1296¦ì­ì¦í¥Á¤¤¡A40·³¥H¤Wªº©~¥Á¿©±w«aª¬°Ê¯ß¤ßŦ¯fªº¨k©Ê¦³2.1¢H¡A¤k©Ê¦³1.1¢H¡A¬ù¬°·í®É¬ü°êMichiganªºTecumseh©~¥Áªº¤T¤À¤§¤@[2]¡C¦Ó¦b¥x¥_¥«1970¦~®Ú¾Ú¶W¹L40·³ªº901¦ì¨k©Ê¤Î745¦ì¤k©Ê¤§©â¼Ë½Õ¬d¡A¥X²{Minnesota Code¤¤class ¢¹¤Îclass ¢º Qªiªº¦û2.98¢H¡A§¹¥þ©Ê¥ª°¼ªKªýÂ_¦û0.24¢H¡A¥H¦¹¦ô­p«aª¬°Ê¯ß¤ßŦ¯f¦Ü¤Ö¦b3.22¢H¥H¤W[3]¡C»PÃú®p·í¦~ªº¬ã¨s¬Û·í¡C

®Ú¾Ú°ê¨¾Âå¾Ç°|1981¦~µoªí¹ï1753¦W¤¤°ê¨k©Ê13¦~¤§°lÂܬã¨s¡A«aª¬°Ê¯ß¤ßŦ¯f¬°¦º¤`­ì¦]¤§²Ä¤G¦ì¡A¶È¦¸©óÀù¯g¡A¸û¸£¤¤­·¬°¦h¡C¤ßµ±µhªºµo¥Í²v¬O26¡þ10000¡þ¦~¡A¤ß¦Ù±ð¶ë¬°16¡þ10000¡þ¦~¡C¨ä¦MÀI¦]¤l¨Ì§Ç¬°°ª¦åÀ£¡B¦~ÄÖ¡B¿}§¿¯f¡B©âµÒ¡A¤ÎªÎ­D¡CÁx©T¾JÁ`¶q»Pµo¥Í²v¨ÃµLÅãµÛ¬ÛÃö¡A¦ý»P¨ä¥L¦MÀI¦]¤l«h¦³¬Û¥[¦¨¤§®ÄªG[4]¡C

«æ©Ê¤ß¦Ù±ð¶ë¦b¦~»´¤H¬Û·í¤Ö¨£¡A¦ýªñ¦~¨Ó«h¦³¼W¥[ªºÁͶաC¥x¤jÂå°|¦b1981¦~³ø§i¤F17¨Ò¦~»´ªº¯f¨Ò¡A¦û¨ä986¨Ò«æ©Ê¤ß¦Ù±ð¶ë¤¤¤§1.7¢H¡A¤j¦h¦³¤£¥u¤@­Óªº¦MÀI¦]¤l¡A¦b11¨Ò¦³°µ¤ß¾ÉºÞªº¯f¨Ò¤¤¡A10¨Ò¦³©úÅã«aª¬°Ê¯ß¯U¯¶¡C°£°Ê¯ßµw¤Æ¥~¡A«aª¬°Ê¯ß®ê¶ë¡BTakayasu¦¡°Ê¯ßª¢¤Î¯Ý³¡®À¶Ë¬Ò¬°¥i¯à¤§¯f¦][5]¡C

TOP

¯f¦]¾Ç
«aª¬°Ê¯ß¤ßŦ¯f¤À«D°Ê¯ßµw¤Æ©Ê¤Î°Ê¯ßµw¤Æ©Ê¨âÃþ¡A«eªÌ¦p¥ý¤Ñ©Ê«aª¬°Ê¯ß²§±`¤Î¤t±T¤ó¯f¾É­P¤§«aª¬°Ê¯ß½Fµ¥¡A¤£¦b¥»³¹±´°Q¤§¦C¡C

¥Ñ°Ê¯ßµw¤Æ¾É­P¤§«aª¬°Ê¯ß¤ßŦ¯f¨ä¯f¦]°ê¤º¤§¥»¤g¬ã¨s¥D­n¦b¦å¯×ªÕ¤Î°ª¦åÀ£¤è­±¡A»P¿}§¿¯f¤§Ãö«Y¥ç¦³¤åÄm´£¤Î¡C¦Ü©ó¨ä¥¦¤§¯f¦]¦p©â·Ï¡BªÎ­D¡B®a±Ú¥v¡BA«¬¤H®æµ¥«h¥¼¨£¥»¤g¤§¤åÄm³ø§i¡C°ª¦åÀ£¦b¦¹¦¸¥xÆW¥»¤gÂåÀø¥t¦³¤@²Õ±M®a¬ã¨s³ø§i¡A¥ç¤£¦b¥»¤å°Q½×¤§¦C¡C

¥x¤jÂå°|¦b1962¦~®Ú¾Ú169¦W«aª¬°Ê¯ßµw¤Æ©Ê¤ßŦ¯f¯f¤H¤Î110¦W°·±d¤H©Ò°µªº¬ã¨sµo²{¡A¥¿±`¤H¤§Áx©T¾J¶q¬°135¡ã220mg/dl¡]177.2¡Ó2.07mg/dl¡^¡A¶W¹L220mgªº¦³5¢H¡A¦Ó«aª¬°Ê¯ßµw¤Æ©Ê¤ßŦ¯f¯f¤H¬°97¡ã353mg/dl¡]225¡Ó4.94mg/dl¡^¡A¶W¹L220mgªº¦³52¢H¡C¨ä¤¤¤ß¦Ù±ð¶ë¸s¬°237.5¡Ó6.5mg/dl¡A¶W¹L220mg/dlªº¦³62¢H¡AÄÝ«æ©ÊªÌ¥­§¡­È¬°249.6mg/dl¡A¶W¹L220mg/dlªº¦³66.6¢H¡AÄݳ¯Â©ʪº¥­§¡­È¬°223mg/dl¡A¶W¹L220mg/dlªº¦û56.8¢H¡A«á¨âªÌ¤§®t§O¨Ã¥¼¹F²Î­p¾Ç¤W¦³·N¸q¤§µ{«×¡C·í®É¥çµo²{«aª¬°Ê¯ßµw¤Æ©Ê¤ßŦ¯f¯f¤H¦í°|´Á¶¡¤§Áx©T¾J¶q®e©öÅܰʡAÅܰʽd³ò¬O82.5¡Ó64mg/dl¡A¦Ó¥¿±`¤H¶È¬°22.5¡Ó22.1mg/dl¡AÅãµÛ¸û¤Ö[6]¡C

¤ß¦Ù±ð¶ë¤Î«aª¬°Ê¯ßµw¤Æ©Ê¤ßŦ¯f¯f¤H¤§¦å¯×¼á²M¾÷¯à®Ú¾Ú1971¦~¥x¤jÂå°|46¦W¯f¤H¤Î26¦W°·±d¤H©Ò°µ¤§¬ã¨s¡A¨Ã¥¼µo²{¦³·N¸qªº®t§O[7]¡C

¤T»Ä¥Ìªo¯×¤Î¦å²M¯×³J¥Õ½è¤§²§±`«¬ºA»P«aª¬°Ê¯ß¤§¬ÛÃö©Ê¦p¦ó¡H®Ú¾Ú¥x¤jÂå°|1977¦~¤§³ø§i¡A127¦W¸g«aª¬°Ê¯ß³y¼vÃҹꤧ±wªÌ»P442¦W°·±dªÌ¤ñ¸ûµo²{¡A°·±d©~¥ÁÁx©T¾J¥­§¡­È177mg/dl¡A¤T»Ä¥Ìªo¯×¥­§¡­È102mg/dl¡A¦Ó»´«×¡B¤¤«×¡A¤Î­««×ªý¶ë±wªÌªº¤T»Ä¥Ìªo¯×­È¤À§O¬°168¡B179¡B255mg/dl¡AÁx©T¾J­È¤À§O¬°193¡B205¡B218mg/dl¡AÅã¥Ü¦å²M¤T»Ä¥Ìªo¯×­È¤§¼vÅT¨Ã¤£¨È©óÁx©T¾J¡C¦Ó¯×³J¥Õ½è²§±`«¬¦b»´«×ªý¶ë¦û49¢H¡A¤¤«×ªý¶ë56¢H¡A­««×ªý¶ë78¢H¡]P<0.001¡^¡A¨ä¤¤¥H²Ä¢¼«¬³Ì¦h¡A¦û48.0¢H¡F¢ºa«¬¦¸¤§¡A7.1¢H¡F¢ºb«¬¦A¦¸¤§¡A4.7¢H¡F¢»«¬³Ì¤Ö¡A2.4¢H¡C¦Ó¥¿±`²Õ²§±`«¬¦³16.2¢H¡A¤À§O¬°¢¼«¬13.4¢H¡A¢ºa«¬1.6¢H¡A¢ºb«¬0.7¢H¡A¢»«¬0.5¢H¡A¦³ÅãµÛ®t²§[8]¡C

¤T­xÁ`Âå°|¦b1982¦~µoªíªº¬ã¨s¤ñ¸û¤F23¦ì¤ßµ±µh¤Î34¦ì¤ß¦Ù±ð¶ë±wªÌ»P80¦ì¥¿±`¤H¡Aµo²{Áx©T¾J¤Î¤T»Ä¥Ìªo¯×Á`¶q¨ÃµLÅãµÛ®t§O¡A¦Ó°ª±K«×¯×³J¥ÕÁx©T¾J¤Î°ª±K«×ÁC¯×½è¦b«aª¬°Ê¯ß¤ßŦ¯f¯f¤H¤À§O¬°38.0¡Ó8.7mg/dl¤Î87.7¡Ó13.1mg/dl¡A¤ñ¥¿±`¤H¤§44.3¡Ó12.4mg/dl¤Î94.1¡Ó15.8mg/dlÅãµÛ¬°§C¡]P<0.01¡AP<0.05¡^¡CÁx©T¾JÁ`¶q»P°ª±K«×¯×³J¥ÕÁx©T¾J¤§¤ñ­È¦b¯f±w²Õ¬°5.1¡Ó1.5¡A¥¿±`²Õ¬°4.4¡Ó1.2¡AÅãµÛ¸û°ª¡]P<0.01¡^¡C§C±K«×¯×³J¥ÕÁx©T¾J»P°ª±K«×¯×³J¥ÕÁx©T¾J¤ñ­È¦b¤ß¦Ù±ð¶ë¸s¬°3.7¡Ó1.5¡A¤ñ¥¿±`²Õ¤§3.0¡Ó1.2ÅãµÛ¸û°ª¡]P<0.05¡^[9,10]¡C

°ª¶¯¥«¥ß¥Á¥ÍÂå°|©ó1986¦~µoªí50¦ì«æ©Ê¤ß¦Ù±ð¶ëªº±wªÌ»P50¦ì¥¿±`¹ï·Ó²Õªº¬ã¨sµo²{¡A¯f±w²ÕÁx©T¾J¡B¤T»Ä¥Ìªo¯×¡B·¥§C±K«×¯×³J¥Õ¡B§C±K«×¯×³J¥Õ¤À§O¬°200.1¡Ó36.6mg/dl¡B137.8¡Ó113.5mg/dl¡B152.2¡Ó152.9mg/dl¡B435.4¡Ó120.5mg/dl¡A¤ñ¥¿±`²Õ¤§183.9¡Ó44.9mg/dl¡B108.2¡Ó68.1mg/dl¡B121.3¡Ó108.0mg/dl339.2¡Ó115.9mg/dl¬Ò°ª¡A¦ý§¡¥¼¹F²Î­p¾Ç¤W¦³·N¸q¤§µ{«×¡C¯f±w²Õªº°ª±K«×¯×³J¥ÕÁx©T¾J¬°43.9¡Ó9.9mg/dl¡A¸û¹ï·Ó²Õªº46.0¡Ó12.0mg/dl¬°§C¡A¥ç¥¼¹F¦³·N¸q¤§µ{«×¡C¯f±w²Õªºapoprotein B«h¸û°ª¡]1.3204¡Ó0.31.3g/l¹ï1.1089¡Ó0.2953g/l¡^¥B¦³©úÅã²Î­p¾Ç¤Wªº®t§O¡]P¡×0.0011¡A<0.01¡^[11]¡C

¦Ü©ó¹B°Ê¤ÎªÀ·|¶¥¼h¹ï«aª¬°Ê¯ßµo¥Í²v¥i¯à¤§¼vÅT¡A°ê¨¾Âå¾Ç°|¦b1968¦~µoªí¹ï102¦ì¤T½ü¨®¥í¤Î1346¦ì°ªªÀ¸g¶¥¼hªº¿ì¤½«Ç¤u§@ªÌ©Ò°µªº¬ã¨sÅã¥ÜÁöµM¤T½ü¨®¥í¤§¹B°Ê­@¨ü¤O¸û¨Î¡AÅé­«¡BÁx©T¾J¡B§¿»Ä¶q§¡¸û§C¡A¦ý¨ä¦h¶¥¼i±a¹B°Ê¤ß¹q¹Ï¤§¶§©Ê²v¨ÃµL®t§O[12]¡C

¿}§¿¯f±wªÌ¿©±w«aª¬°Ê¯ß¤ßŦ¯fªº±¡ªp¦p¦ó¡H¥x¤jÂå°|¦Û¥Á°ê45¦~¨ì50¦~¦@391¨Ò¦í°|´Á¶¡°µ¹L¤ß¹q¹Ï¤§¿}§¿¯f±wªÌ¤¤¦³35¨Ò¡]8.95¢H¡^¦³¤ß¦Ù±ð¶ë¤§ÅܤÆ[13]¡A¤ñ¨Ò¬Û·í°ª¡C

TOP

Á{§Éªí²{¤Î¹êÅç«ÇÀˬd
«aª¬°Ê¯ß¤ßŦ¯f¥i¯à¤§Á{§Éªí²{¬Û·í¦h¼Ë¤Æ¡A°£¤F«æ©Ê¤ß¦Ù±ð¶ë¡BºC©Êí©w«¬¤ßµ±µh¡B¤£Ã­©w«¬¤ßµ±µh¡B¯Ê¦å©Ê¤ß¦Ù¯f¡B²§«¬¤ßµ±µhµ¥¥~©|¦³¦U¦¡¦U¼Ë¤§¤ß«ß¤£¾ã¡B¶Ç¾Éªýê¡A¤Î³Ì¥i©ÈªºÖ`¦ºµ¥¡C¦Ó¯f¤H«h±`¸g¾ú¤W­zÁ{§É¼x­Ô¸s¤¤¤£¥u¤@¼Ë¤§ªí²{¡C¥[¤Wªñ´X¦~¨Ó¦UºØ¥ý¶i»ö¾¹¦b¥xÆW¤§´¶¤Î©M¤º¥~¬ìªvÀøªº¶i¨B¡AÁ{§Éªí²{¤Î¹w«á¥ç¤j¦³¤£¦P¡C¸ê°Tµo¹F¤Î¬ã¨s­·®ð¶i¨B¥ç¨Ï±o§ë¥Z©ó°ê¥~¤§¤åÄm¸û±q«e¤j´T¼W¥[¡A¦]¤§¦¬¶°§ó¬°§xÃø¡A±¾¤@º|¸U¡A¦b©ÒÃø§K¡A¦p¦³ÅªªÌµo²{¦³¥¼³Q¤Þ¥Î¤§¥»¤g¸ê®Æ»P«aª¬°Ê¯ß¤ßŦ¯f¬ÛÃöªº¡A½Ð´f¤©´£¨Ñ«ü¾É¡C¥Ø«e¶È´N¤â¤W¤w¦³¤§¸ê®Æ»PŪªÌ¦@¨É¡C
¤@¡B ²§«¬¤ßµ±µh
¡@ °ê¤º¶È¨£¹s¬Pªº³ø§i¡A¦ü¥G¨Ã¤£¦h¨£¡C

1974¦~°ª¶¯Âå¾Ç°|µo²{¤@¨Ò56·³¤k©Ê¡A¦]5¤Ñ¥H¨Ó¨C©]ºÎ¯v«eµo¥Í¯Ý³¡¤£¾A¡AÀHµÛµo¥ÍÀY·w¡A¨C¦¸5¨ì10¤ÀÄÁ¡A¨C¤éµo§@1¦Ü3¦¸¡A¤ß¹q¹Ï§e²{Äu©Ð¶Ç¾Éªýº¢¤Î¸É¥R¦¬ÁY¡A¤ß«Ç«ß32/min¡A¦blead ¢º¡B¢»¡BaVF¥i¨£¨ìST¤§¤Wª@¡Alead¢¹¡BaVL¡BV2¦ÜV5¦³»´«×¤§ST¤U­°¡A«ùÄò¬ù5¤À30¬í¡C¸gPETN¨C¤Ñ20mg¤§¤fªAªvÀø«á§Y¤£¦Aµo§@¡A¶EÂ_¬°²§«¬¯U¤ß¯g[14]¡C

1977¦~ºa¥ÁÁ`Âå°|³ø§i¨â¨Ò«aª¬°Ê¯ßµjÅˤ§¯f¨Ò¡A¦û¨ä140¨ÒºÃ¦ü«aª¬¯ß¯f¦Ó°µ¤§«aª¬°Ê¯ßÄá¼v¤¤¤§1.4¢H¡C¨ä¤¤¤@¨Ò¬°50·³¨k©Ê¡A¦³Prinzmetal¤ó²§«¬¤ßµ±µh¡AµL¦³·N¸q¤§«aª¬°Ê¯ßªý¶ë¡A¨Ï¥ÎÀR¯ßª`®gªüº¸ªkµÇ¤W¸¢¨ü¾¹¨ë¿E¯À«á²£¥ÍªñºÝ¥k«aª¬°Ê¯ß¤§µjÅË¡A¸g¦Þ¤Uµv»Ä¥Ìªo¤ùªvÀø«á®ø¥¢¡C¥t¤@¨Ò¬°60·³¨k©Ê¡A¦³¤£Ã­©w¤ßµ±µh¤Î©T©wªñºÝ¥ª«e­°°Ê¯ß¯U¯¶¡AÄá¼v¤¤¦]¸Ó³BµjÅ˦ӧ¹¥þªý¶ë¡A¨Ï¥Î¦Þ¤Uµv»Ä¥Ìªo¤ù«á¦nÂà[15]¡C

°ê®õÂå°|©ó1985¦~¥ç³ø§i¤@¨Ò41·³¨k©Ê¦³©]¶¡¤ßµ±µh¥B¦ñ¦³µs¦½¡A24¤p®ÉHolter¤ß¹q¹Ï¦b²M±á5ÂIµo²{¹F0.6mV¤§ST¬q¤É°ª«ùÄò3¤ÀÄÁ¤§¤[¡A¨ä«aª¬°Ê¯ßÄá¼v¬°¥¿±`¡C©ó¨Ï¥Înifedipine 10mg qid¤Îisosorbide dinitrate 10mg qid«á¨ä¯gª¬§¹¥þ®ø°£[16]¡C

¤G¡B ¤£Ã­©w«¬¤ßµ±µh
¡@ °ê¤º±´°Q¤£Ã­©w«¬¤ßµ±µhªº¤åÄmµ§ªÌ¦¹¦¸¶È¦¬¶°¨ì¤@½g¡A¬O¥Ñ¥x¤jÂå°|©ó1978¦~©Òµoªí[17]¡C¸Ó½g¤å³¹¦¬¶°1973¦~12¤ë¦Ü1978¦~4¤ë¶¡64¦WÁ{§É¤W§e²{¤£Ã­©w«¬¯U¤ß¯g¤§±wªÌ¡A3­Ó¤ë¤º¦³¤ß¦Ù±ð¶ë¤§±wªÌ¬Ò¤w±Æ°£¡A¨C¦W¬Ò¬I¥H¤ß¾ÉºÞ¡B«aª¬°Ê¯ßÄá¼v³NÀˬd¤Î¦å¬y¤O¾Ç´ú©w¡A¨ä¤¤39¦W±wªÌ¨Ã±µ¨ü¥~¬ì«aª¬°Ê¯ß¶¹D¤â³N¡Cµ²ªGµo²{¦³3¦W¡]5¢H¡^«aª¬°Ê¯ß³y¼v¥¿±`¡C¦³¤ß¦Ù±ð¶ë¯f¥vªÌ34¦W¡A¨ä«aª¬°Ê¯ßªý¶ëµ{«×¸û­«¡A¥ª¤ß¥\¯à«ü¼Ð¸û¦H¡C61¦W±wªÌ¤¤¡A¤ßµ±µh©ó¦í°|2¤Ñ«á¤´«ùÄòªÌ10¦W¡A§ïµ½ªÌ51¦W¡A«e¯f¸s¤§¥ª¤ß«Ç¥\¯à¸û«á¯f¸s¬°¦H¡C¤@¦W±wªÌ©ó¤ß¾ÉºÞÀˬd«á5¤p®É¦º¤`¡A¨ä«aª¬°Ê¯ß¥D·F¦³­««×ªý¶ë¡C°£¦¹±wªÌ¥~¡A60¦W¤¤¦³39¦W±µ¨ü«aª¬°Ê¯ß¶¹D¤â³N¡A¨ä¤¤2¦W¡]5¢H¡^¨Öµo¤ß¦Ù±ð¶ë¡A3¦W¡]8¢H¡^³N«á¦º¤`¡F¦Ó21¦W±µ¨ü¤º¬ìÀøªkªÌ¡A2¦W¡]10¢H¡^¨Öµo¤ß¦Ù±ð¶ë¡A1¦W¡]5¢H¡^¦º¤`¡C¥X°|«á¡A¤º¬ìªvÀø¸s°lÂÜ¥­§¡23­Ó¤ë¡]5¦Ü54­Ó¤ë¡^¡A3¦W¡]15¢H¡^¦º¤`¡A¥~¬ìªvÀø¸s°lÂÜ25­Ó¤ë¡]4¦Ü55­Ó¤ë¡^¡A¥ç¦³1¦W¡]3¢H¡^¦º¤`¡C¤º¥~¬ìªvÀø¤§¦º¤`²v®t²§¥¼¹F²Î­p¤W¤§¦³·N¸q¡A¦ý¹ï¤ßµ±µh¤§§ïµ½¥~¬ìÀøªk¸ûÀu¡A35¦W¥~¬ìªvÀø¥Í¦sªÌ¤¤25¦W¡]71¢H¡^¤ßµ±µh®ø¥¢¡F¦Ó¤º¬ìªvÀø17¦W¥Í¦sªÌ¤¤¡A¶È5¦W¡]29¢H¡^¤ßµ±µh¸Ñ°£¡]P<0.01¡^¡C
¤T¡B «æ©Ê¤ß¦Ù±ð¶ë
¡@ ¢°¡DÁ{§É¯fµ{¤§·§Æ[
¥x¤jÂå°|¦b1960¦~³ø§i¹ï73¨Ò±q1954¦~1¤ë¨ì1959¦~12¤ë¦í°|¸g¨t¦C¤ß¹q¹ÏÃҹꬰ¤ß¦Ù±ð¶ë¤§¯f¨Ò©Ò°µªºÆ[¹î¡A¨C¦~ªº¯f¨Ò¦û©Ò¦³¦í°|¤§¤ßŦ¦åºÞ¯e¯f¦Û1954¦~ªº1.8¢H¼W¥[¦Ü1954¦~ªº18.3¢H¡C¨k¤k©Ê§O¤ñ¬°5.6¤ñ1¡Cµo§@¥­§¡¦~ÄÖ¬°57·³¡A¨k©Ê¬°55·³¦Ó¤k©Ê¬°66.3·³¡A72¢Hµo¥Í©ó50¦Ü75·³¡C©ó¬K¤Ñµo¥Í²v³Ì§C¡A¦Ó®L¤Ñ¸û¦h¡C¥ô¦ó¾·~³£¦³¡A¦ý¦ü¥G¸û©öµo¥Í©ó¤ÖÅé¤O¬¡°Êªº³£¥«©~¥Á¡C»P³Ü°s¦ü¥GµLÃö¡A¦ý§l·ÏªÌ¬°¤£§l·ÏªÌªº¨â­¿¡Cµo§@®É¤§¬¡°Êª¬ªp¨ÃµL¯S§O¡A¤j¦h¼Æ¬Ò¦b¥ð®§®Éµo¥Í¡C¦³°ª¦åÀ£ªÌ¥e69.9¢H¡A¦³¿}§¿¯fªÌ¦û17.8¢H¡Cµo§@«e¦³¤ßµ±µhªº¦³20.5¢H¡C60¢H¦³¨å«¬ªº¯Ýµh¡A23.1¢H¯Ýµh¬°«D¨å«¬¡A¦Ó15.4¢H«hµL¯Ýµh¡C¨ä¾l¥D­n¯gª¬¬°µs¦½¡B©I§l§xÃø¡B¹Ã¦R¡BÀY·w¡Bäú¤ß¡Bµê®z¡A¤Î¥|ªÏ¦B§N¡C26¨Ò48¤p®É¤º¦í°|ªÌ¦³23¨ÒÅé·Å¤É°ª¡A³q±`¦b38¢J¡A2¶g¤º«ì´_¥¿±`¡A¦Ó¨ä¤¤25¨Ò¦³¥Õ¦å²y¼W¥[¡AESR«h¥þ³¡¤É°ª¡C¤ß¹q¹ÏÅã¥Ü¥H«e¾À¤ß¦Ù±ð¶ë³Ì¦h¡A¦³54.7¢H¦³¤ß«ß¤£¾ã[18]¡C

¦¨¥\¤j¾Ç¦b1991¦~³ø§i¤F1988¦~8¤ë¦Ü1990¦~7¤ë¦¬¶°¤§204­Ó«æ©Ê¤ß¦Ù±ð¶ë¯f¤H¡C¨ä¤¤138¤H¦b¯gª¬¥X²{24¤p®É¤º¤J°|¡A¾Ú¦¹¬°¤ÀªR¹ï¶Hµo²{110­Ó¨k©Ê¡A28­Ó¤k©Ê¡A¥­§¡¦~ÄÖ62.6¡Ó11.3·³¡C99­Ó¦b6¤p®É¤º¤J°|¡A¨ä¤¤60¦W±µ¨ü¤FÀR¯ßstreptokinaseªvÀø¡A¦í°|¶¡¦º¤`²v¬°16.7¢H¡F¦Ó¨ä¾l39¦W¥¼¥ÎstreptokinaseªvÀøªÌ¦í°|¶¡¦º¤`²v¬°28.2¢H¡Cµo§@¶W¹L6¤p®É¤~¦í°|ªº¦º¤`²v¬°7.7¢H¡C¦í°|®É¤§Æ{¦å©Ê¤ßŦ°IºÜKillip class ¢»©Î¢¼¤§¤ñ¨Ò¦b6¤p®É¤º¨Ó°|ªÌ¦³30.7¢H¡A¶W¹L6¤p®ÉªÌ«h¬°7.6¢H¡A¥i¨£¯gª¬»´ªº¦ü¥G¸û±ß¨ì°|ªvÀø¡A¦]¦¹¦º¤`²v¥ç¸û§C¡C¾ãÅ馺¦]¤ÀªRÆ{¦å©Ê¤ß°IºÜ¬°79¢H¡A¤ß«Ç©Ê¤ß«ß¤£¾ã¬°8¢H¡A¨ä¥L¤º¬ì¯e¯f¦û13¢H¡C¾ãÅé¦í°|¦º¤`²v¬°17.4¢H[19]¡C

ºaÁ`©ó1991¦~µoªí[20]63¨Ò¦Û1989¦~9¤ë¦Ü1990¦~1¤ë¨ì«æ¶E´NÂ媺«æ©Ê¤ß¦Ù±ð¶ë±wªÌ¤§¤ÀªR¡Aµo²{´XÂI­È±oª`·Nªº²{¶H¡A(1)9.5%(6/63)ªº¯f¤H¨Ï¥Î¬F©²ªº±ÏÅ@¨®¡F(2)89%¨Ó¦Û¥~¦a¡A62%¥Ñ¶}·~Âå©ÎªÀ°ÏÂå°|ªº«æ¶E³BÂश¡F(3)¦³5¦ì(7.9%)¦]¤£ª¾¹D¯Ýµhªº¦MÀI©Ê¦Ó©µ»~°eÂå¡F(4)50%ªº¯f¤Hµo¥Í©óºÎ¯v¤¤¡F(5)µo§@ªº®É¶¡³Ì¦h¦b²M±á0ÂI¦Ü6ÂI¡F(6)ÁöµM63.5%ªº¯f¤H¦bµo§@«á6¤p®É¤º¨ì«æ¶E¡A¦ý¶È12.7%¥H¦å®ê·»¸ÑÀøªkªvÀø¡F(7)¯f¤H¥­§¡¦b«æ¶E¼È¯d¤F¶W¹L4­Ó¤p®É¡C

¦Ü©ó¦~ÄÖªº¼vÅT¡A¥x¤jÂå°|©ó1991¦~µoªí[21]®Ú¾Ú¸Ó°|1980¦~1¤ë¦Ü1989¦~4¤ë¦@742¨Ò«æ©Ê¤ß¦Ù±ð¶ë±wªÌ©Ò°µ¤§¬ã¨sµo²{¡A65·³¥H¤W¤§321¦W¯f¤H»P65·³¥H¤U¤§421¦W¯f¤H¤ñ¸û¨ä¯S¦â¦³(1)¨k©Ê¤ñ¨Ò¸û¤Ö(71.3¢H vs. 88.1¢H)¡A(2)¦³¯ÝµhªÌ¸û¤Ö(72¢H vs. 86.5¢H)¡A(3)¤ßŦ¥\¯à¨ü·l¸û­«¡A¦p¤ßŦ°IºÜ(35.2¢H vs. 20.2¢H)¡BKillip class ¢»©Î¢¼(35.4¢H vs. 21.1¢H)¬Ò©úÅã¸û¦h¡A¦ý¥ð§J¤§¤ñ²v«h±µªñ(5.9¢H vs. 4.5¢H)¡A(4)¨Öµo¯g¸û¦h¡A¦p§C¦åÀ£¡B§C¤ß·i¿é¥X¶q¡BªÍ¤ô¸~¡BÀWÁc¤ß«Ç¦­´Á¦¬ÁY¡B¤ß©ÐŸ°Ê©Î²Ó°Ê¡B§¹¥þ©Ê¤ßŦ¶Ç¾ÉªýÂ_¡B¤Î¤ß«Ç¤º¶Ç¾É»Ùêµ¥¡A¦ý¤ß«Ç¤¤¹j¯Ê·l¡B¤ß«Ç©Ê¤ß·i¹L³t¡B¤Î¤ß«Ç²Ó°Êµ¥«hµL®t§O¡A(5)°lÂÜ5¦~¨ä¦º¤`²v¤´¸û°ª¡C

¢±¡D«æ©Ê¤ß¦Ù±ð¶ë¤§¶EÂ_
«æ©Ê¤ß¦Ù±ð¶ë¤§¶EÂ_¶Ç²Î¤W¬Ò¥H¨å«¬ªº¯Ýµh¡B¤ß¹q¹ÏªºÅܤơA¤Î¤ß¦Ùþùªº¤É°ªµ¥¤TªÌ¦³¨ä¤G¬°¨Ì¾Ú¡A¦³Ãö¤ß¹q¹Ï¤è­±¨å«¬ªº«e¾À¤Î¤U¾À¤ß¦Ù±ð¶ëÀ³µL§xÃø¡A¦Ó°ª«e°¼¤ß¦Ù±ð¶ë¤Î«á°ò³¡¤ß¦Ù±ð¶ë«h¸û¦³¿³½ì¡C®Ú¾Ú¥x¤jÂå°|1972¦~µoªí¹ï6¨Ò¨å«¬°ª«e°¼¤ß¦Ù±ð¶ë¤Î171¦W«C¦~¤H©Ò°µ¹ï·Ó¬ã¨s¡AÀ|¸Õ¥H©Ò¿×°ª¦ì«e¯Ý³¡¤ß¹q¹Ï¡]¤ñ³q±`¤§«e¯Ý³¡¤ß¹q¹Ï°ª¤@¦Ü¤T­Ó¦Ø¶¡¡^»²§U¶EÂ_°ª«e°¼³¡¤ß¦Ù±ð¶ë¯g¡AÀò±oµ²½×¦p¤U¡G1.°ª¦ì«e¯Ý³¡¤ß¹q¹Ï¦³ÅãµÛQr©ÎQSªi¡A2.¦blead I¡BaVL¤Î¥ª«e¯Ý¤Î¨ä°ª¦ì¤ß¹q¹Ï¦³©úÅ㤧ªìrªi¤§´î¤Ö¡A3.¦³¨å«¬¤§¯Ýµh¦Ó¦b°ª¦ì«e¯Ý³¡¤ß¹q¹Ï¥X²{­Ë¥ß¡]³±¦V¡^Tªi¡A4.Prinzmetal©Òµoªí¤§ªìrªi¦b²Ä¤G¦Ø¶¡¤§V2¤Î²Ä¤T¦Ø¶¡¤§¤¤¶¡¹q·¥¤§®ø¥¢¬°¶EÂ_°ª¦ì«e°¼³¡¤ß¦Ù±ð¶ë¯g¤§®Ú¾Ú¡A¦ü¥G¤£¨¬±Ä«H[22]¡C¦Ó«á°ò³¡¤ß¦Ù±ð¶ë®Ú¾Ú¥x¤jÂå°|1975¦~¹ï7¨Ò¦³¨å«¬Á{§É¸g¹L©M¸g¥ßÅé¤ß¹q¹Ï¤Î­¹¹D¹q·¥¤ß¹q¹ÏÃҹꤧ¯f¨Ò»P171¨Ò°·±d¤H©Ò°µ¤§¹ï·Ó¬ã¨sµo²{¡G1.¦b¥k¯Ý¹q·¥¯S§OV1¦³R/S¡Ù1¨Ö¦³¦V¤WTªi¬°¤@­«­n¤§ÃÒ¾Ú¡A2.«e¯Ý¹q·¥¤§¹L´ç¦a±a¤§®ø¥¢¥ç¬°¤@¦³¤O¤§ÃÒ¾Ú¡A3.¨äQRS¦V¶b¤D¦V¥ª¤U«e¦Ó«D¥ª¤U«á¡AT¦V¶b«h¤ñ¥¿±`¤H§óÁͦV«e¤è¡A¬O¨ä¯SÂI[23]¡C

¤ß¦Ùªº¬ã¨s¡A1962¦~¥x¤jÂå°|µoªíSGOT¦b«aª¬°Ê¯ß¯f±wªÌ¦å²G¤§ÅܤơAµo²{³¯Â©ʤߦٱð¶ë¤Î¯U¤ß¯g±wªÌ¬ÒµL¤W¤É¡A¦Ó25¨Ò«æ©Ê¤ß¦Ù±ð¶ëªÌ¨C¤@¨Ò§¡¦³¤É°ª¡C¨ä¶q©óµo¯f¤§¦¸¤é¤É¦Ü³Ì°ª¡A¥H«á³vº¥¤U­°¡A¤j¦h©ó6¤é¤º«ì´_¥¿±`¡A¥B¨ä­È°ª©ó500u/cc.ªÌ¯f±¡§¡·¥¬°ÄY­«¦Ó¦º¤`²v°ª[24]¡C1977¦~µoªícreatine phosphokinase¤Îlactatedehydrogenaseµ¥¤Î¨äisoenzyme¤§¬ã¨sµo²{¦b12­ÓÃҹꬰ«æ©Ê¤ß¦Ù±ð¶ë¤§¯f¨Ò¨äCPK-MB¬Ò¤j©ó1.5¢H¡]1.5¢H¡ã16.1¢H¡^Á`¶q¬°8¡ã182IU¡A72¤p®É¤º®ø¥¢¡C5¨Ò¤ß¹q¹Ï¦³¯Ê¦å©Î¶Ë®`ÅܤƪÌSGOT¬Ò¤£°ª¡A¦ýCPK-MB«o¬°¶§©Ê¡AÅã¥Ü¤´¦³¤ß¹q¹Ï¤£ÅãµÛ¤§¤ß¦Ù±ð¶ë¡CLDH1¤ÎLDH2¤§¤É°ª¦bµo§@«á72¤p®É«h¤´µM«ùÄò¡A¹ï©ó©â¦åÀˬd®É¶¡©µ¿ðªÌ¦³¨ä»ù­È[25]¡C¤¤¤sÂå¾Ç°|¦b1979¦~µoªí42¨Ò¶EÂ_¬°«æ©Ê¤ß¦Ù±ð¶ëªÌ¨äCPK¡BCPK-MB¡BLDH¡B£\-HBD¡]alpha-hydroxybutyric dehydrogenase¡^¡BGOT¤ÎECG¤§¶EÂ_²v¡A¨äµ²ªG¦pªí¤@¡C¥Ñ¨ä¤ñ¸û¥iª¾¡ACPK-MB¦P®É¨ã¦³¸û°ª¤§±Ó·P©Ê¡B¯S²§©Ê¡A»P¹w´ú¥¿½T²v¡A¦ýÀ³©ó¯fµo«á72¤p®É¤º´ú¶q[26]¡C

¢²¡D«æ©Ê¤ß¦Ù±ð¶ë¦X¨Ö¥k¤ß«Ç¤ß¦Ù±ð¶ë
¤@¯ë¤ß¦Ù±ð¶ë¥D­n¬O«I¥Ç¥ª¤ß«Ç¾À©Î¤ß«Ç¤¤¹j¡A¦Û1974¦~Cohn³ø§i6¨Ò¦X¨Ö¥k¤ß«Ç¤ß¦Ù±ð¶ë¤§¯f¨Ò«á¡A¥k¤ß«Ç¤ß¦Ù±ð¶ë¯g¤è¤~³vº¥¬°¤H©Ò­«µø¡C°ê¤º¤åÄm¤£¦h¡Aªø©°Âå°|¦b1982¦~µoªí¨ä4¦~¶¡210¨Ò«æ©Ê¤ß¦Ù±ð¶ë¤¤6¨Ò¦ñÀH¥k¤ß«Ç¤ß¦Ù±ð¶ë¤§¯f¨Ò¡A¬Ò¬°¥ª¤ß«Ç¤U¾À¤ß¦Ù±ð¶ë¡A¬Ò¥X²{ÀVÀR¯ß¦±±i¡A¨ä³Ì°ª¤¤¤ßÀR¯ßÀ£¤¶©ó18cmH~\2~ZO¦Ü30cmH~\2~ZO¤§¶¡¡A¥­§¡¬°23¡Ó5cmH~\2~ZO¡A¬Ò¦ñÀH¦³§C¦åÀ£¡]¦¬ÁYÀ£§C©ó80mmHg¡^¡C°£¤@¨Ò¦X¨Ö§¿¬r¯gªÌ¥~¡A¨ä¾l5¨Ò¯f¤H¯Ý³¡X¥ú¤ù¬ÒµLªÍ³¡Æ{¦å²{¶H¡C3¨Ò¸ËSwan-Ganz¾ÉºÞ¡A¨ä³Ì°ª¤§CVP©Î¥k¤ß©Ð§¡À£¡]¥­§¡­È¬°20¡Ó3mmHg¡^§¡°ª©óPCWP¡]ªÍ·L¦åºÞ·¤À£¡^¡]¥­§¡­È¬°14¡Ó4mmHg¡^¡C¥t¥~3¨Ò®Ö¤lÂå¾Ç¤ßŦ°{Ã{Äá¼v¡]technetium-99m pyrophosphate myocardialscintigraphy¡^Åã¥Ü¦³¥ª¤ß«Ç¤U¾À¤Î¥k¤ß«Ç¾À±ð¶ë²{¶H¡C¨ä¤¤3¨Ò¨ÖµoAdams-Stokes syndrome¡C6¨Ò¤¤1¨Ò¦º¤`¡A¦¹¯f¨Ò¦X¨Ö¦³§¿¬r¯g¡F¨ä¾l5¨Ò§¡±d´_¡CÁ{§É¤W¥ª¤ß«Ç¤U¾À¤ß¦Ù±ð¶ë¯f¤H­Y¥X²{ÀVÀR¯ß¦±±i¡AªÍ³¥µLÅo­µ¡]©Î»´·LÅo­µ¡^¡B§C¦åÀ£¬Æ¦Ü¥ð§J¡A§YÀ³ÃhºÃ¦³§_¦X¨Ö¥k¤ß«Ç¤ß¦Ù±ð¶ë¡C¶EÂ_¤W°£¤FÀ£¤Oªº´ú©w¡]CVP¤ÎPCWP¡^¥~¡A§Q¥Îtechnetium-99m pyrophosphate¤ßŦ°{Ã{Äá¼v¬O¬Û·í¦³»ù­Èªº¡C¶EÂ_ªº¥Øªº¦b©óÁ×§K¤£¾A·í¤§¿é²G­­¨î©Î±j¯P§Q§¿¾¯ªºªvÀø¡A¬Û¤Ï¦a«hÀ³¤©¾A·í¤§¿é²GªvÀø¤Îcardiotonic agents¦pdobutamineµ¥[27,28]¡C

¢³¡D«æ©Ê¤ß¦Ù±ð¶ë¨Öµo¤ß«Ç¤¤¹j¯Ê·l
«æ©Ê¤ß¦Ù±ð¶ëªº¾÷±ñ©Ê¨Öµo¯g®Ú¾Ú¥~°ê¤åÄm³ø§i³Ì¦h¬°¦Û¥Ñ¾À¯}µõ¡A¨ä¦¸¬°¤ß«Ç¤¤¹j¯Ê·l¤Î¨Å¬ðª¬¦ÙÂ_µõ¡C°ê¤º¦³³ø§iªÌµ§ªÌ¶È¦¬¶°¨ì¤T½g¦³Ãö¨Öµo¤ß«Ç¤¤¹j¯Ê·l¤§¤åÄm¡AÁöµM¨ä¥¦¨âÃþ¨Öµo¯g³\¦hÁ{§ÉÂå®v¬Ò´¿¥Ø¸@¡A±¤¥¼µÛ¦¨½×¤å¡A¸Ô±¡¤£±o¦Óª¾¡C

1977¦~¥x¤jÂå°|­º¦¸µoªí¤@¨Ò©ó«æ©Ê«e¤¤¹j¤ß¦Ù±ð¶ë«á17¤p®É¨Öµo¤ß«Ç¤¤¹j¯Ê·l¤§55·³¤k©Ê¡A¯f¤H¬ðµM¥X²{±j¾Ù¤ßÁYÂø­µ¡A¤ßÁY§Ý°Ê¡A­««×¤ßŦ¤Î¤ßŦ¦åºÞ±Y¼ì¡A¤ß¹q¹Ï·s¥X²{¥k§ôªK¶Ç¾Éªýº¢¡C©ó²Ä¥|¤Ñ§Q¥ÎSwan-Ganz¶¶¬y¾ÉºÞ°µ§ÉÃä¥k¤ß«Ç¤ß¾ÉºÞÀˬd¡AÃÒ¹ê¦b¥k¤ß«Ç¦³¤@¥ª¦V¥k¤ß«Ç¦å¬y°{°Ê¡A¨äªÍ°Ê¯ß¬y¶q»P¥þ¨­°Ê¯ß¦å¬y¶q¤ñ¬°2¡G1¡A©ó²Ä¤C¤Ñ´c¤Æ¦º¤`[29]¡C1981¦~¥x¤jÂå°|²Î­p240¨Ò¤ß¦Ù±ð¶ë¡A¨ä¤¤¦³4¨Ò¨Öµo¤ß«Ç¤¤¹j¯Ê·l¡A¦û1.7¢H¡Cµo¥Íªº®É¶¡¦b±ð¶ë«á17¤p®É¦Ü8¤Ñ¡A¥­§¡2.9¤Ñ¡C¦³¥|ÂIÀ³¤Þ°_¦¹¶EÂ_¤§°ª«×ÃhºÃ¡G1)¦b¯Ý°©¥ª½t¤Î¥ª¯Ý«e°Ï¥X²{¤jªº¦¬ÁYÂø­µ¤Î¥iIJºN©ÊŸ°Ê¡A¥B¦ñ¦³¦å¦æ¤O¾Çª¬ªp¤§«æ¼@´c¤Æ¡F2)CVP¤É°ª¡F3)¯Ý³¡X¥ú¤ù¥X²{¤ßŦÂX¤j¤Î°Ê¯ß¥R¦å¡F4)¦b«æ©Ê«e¤¤¹j©Î¼s¦Æ«e¾À¤ß¦Ù±ð¶ëªÌ¥X²{¤ß¹q¹Ï¤WRBBBªºÅܤơC¨ä¶EÂ_¬Ò¾a§ÉÃä¥HSwan-Ganz¾ÉºÞ°µ¥k¤ß¤ß¾ÉºÞÀˬd½T¥ß¡C¨ä¤¤¤T¨Ò¦b2¦Ü11¤Ñ¤º¦º¤`¡A¶È¤@¨Ò±µ¨ü¥~¬ì¤â³N­×¸É¯Ê·l¤Î¤Á°£¥ª¤ß«Ç¦Ù½FªÌªø´Á¦s¬¡[30]¡C1983¦~°¨°ºÂå°|¤]³ø§i¤@¨Ò©ó«æ©Ê¼s¦Æ©Ê«e¯Ý¾À¤Î¤U¾À¤ß¦Ù±ð¶ë«á13¤p®É¨Öµo¤ß«Ç¤¤¹j¯}·l¤§61·³¨k©Ê¡C³N«eªÍ°Ê¯ßÀ£°ª¹F87/27mmHg¡B¥ª¤ß«Ç¦y½F¡B¥k«aª¬°Ê¯ß¤Î¥ª«e¤UªÏ­««×ªý¶ë¡BªÍ¦å¬y»PÅé¦å¬y¤ñ¬°3.2¡G1¡C¯f¤H©ó±ð¶ë«á10¶g±µ¨ü¶}¤ß¤â³N¡A¥]¬A¤¤¹j­×¸É¡B¤ß«Ç½FºPÅ|³N¤ÎÁôÀR¯ß¶¹D¤â³N¡C³N«á±¡ªp¤j¬°§ïµ½¡A2­Ó¤ë«á°lÂÜÀˬdµo²{¥ª¤ß«Ç¥\¯à§ïµ½¡AªÍ°Ê¯ßÀ£24/10mmHg¡AÁôÀR¯ß¶¹D¤â³N¦¨¥\[31]¡C

¢´¡D«æ©Ê¤ß¦Ù±ð¶ë¨Öµo¶Ç¾Éªýº¢
¥x¤jÂå°|©ó1972¦~³ø§i104¨Ò©ó¤ß¦Ù±ð¶ëµo§@24¤p®É¤º¦í¶i¤º¬ì«æ±Ï«Ç¯f±w¤§¶Ç¾Éªýº¢¡A«e¾À±ð¶ë¦û68¢H¡]71¦W¡^¡A¤U¾À±ð¶ë¡]¥]¬A«á¾À¡^¦û32¢H¡]33¦W¡^¡C¦@50¦W¡]48¢H¡^¦X¨Ö¦³¦UºØ§Î¦¡¤Î¦UºØµ{«×¤§¤ßŦ¶Ç¾Éªýº¢¡C¨£ªí¤G¤Îªí¤T[32]¡C

©Ð«Ç¶Ç¾Éªýº¢¤§µo¥Í¦p©ó¤U¾À±ð¶ë¡A¤j³¡¤À©óµo§@«á24¤p®É¤º¥X²{²Ä¤@«×ªýº¢¡A¨ä¤¤¦³¤@¹L©Ê¡AÀH§Y´_­ì¡A¦ý¤j³¡¤À¤£¤[§Y¶i¤J²Ä¤G«×¤Î²Ä¤T«×ªýº¢¦Ó©ó¤@©P¤º¥Ñ¬Û¤Ï¶¶§Ç´_­ì¡C¥Ã»·¿ò¯d¶Ç¾Éªýº¢ªÌ·¥¬°µ}¤Ö¡C¤U¾À±ð¶ë¨Öµo©Ð«Çªýº¢¤§¯f¤H¦º¤`²vµLÅãµÛ¼W¥[¤§²{¶H¡C¶È¦³¤@¨Ò¤U¾À±ð¶ë¨Öµo²Ä¤T«×©Ð«Ç¶Ç¾Éªýº¢ªÌ©ó©ü­Ë«á°e¦ÜÂå°|¤w§e¥ð§Jª¬ºA¡A4¤p®É«á«Å§i¦º¤`¡C¤U¾À±ð¶ë¥X²{©Ð«Çªýº¢¤§­ì¦]¤D¦b©ó©Ð«Çµ²¸`¦¨bundle of His¤§¤@¹L©Ê¯Ê®ñ¡B¤ô¸~©Îµoª¢¡A¬G¦h¬°¤@¹L©Ê¡A¥B¹w«á¸û¨Î¡C¤Ï¤§¡A«e¾À±ð¶ë¦p¨Öµo²Ä¤T«×©Ð«Ç¶Ç¾Éªýº¢¡A§Yªí¥Ü¦³¨â°¼¶Ç¾É§ôªK¤§°ª«×·l¶Ë©Î¦X¨Ö¤U¾À¡B©Ð«Çµ²¸`¤Îbundle of His¤§¦å¦æ»Ùê¡A¬G¯f¤H±`§e¥ð§J©Î¤ßŦ°IºÜ¦Ó¦º¤`¡A¦º¤`²v°ª¹F60¢H¦Ü100¢H¡C

°ª¶¯Âå¾Ç°|©ó1979¦~³ø§i¨ä197¨Ò¤ß¦Ù±ð¶ë¤¤¦³12¨Òµo¥Í§¹¥þ©Ð«Ç¶Ç¾Éªýº¢¡A11¨Ò¬°¤U¾À¤ß¦Ù±ð¶ë¡Aµo¥Í²v¬°©Ò¦³¤U¾À¤ß¦Ù±ð¶ë67¦W±wªÌ¤§16¢H¡A¦Ó1¨Ò¬°«e¾À¤ß¦Ù±ð¶ë¡A¦û©Ò¦³«e¾À¤ß¦Ù±ð¶ë119¦W¤§¤£¨ì1¢H¡C2¨Ò¦º¤`¡A¤@¨Ò§Y¬°«e¾À¤ß¦Ù±ð¶ëªÌ¡C¥i½Tª¾µo¥Í®É¶¡ªÌ¦³11¨Ò¡A¬Ò©ó±ð¶ë«á4¤Ñ¤ºµo¥Í¡A¥Í¦sªÌ¤¤8¨Ò©óµo¥Í«á4¤Ñ¤º®ø¥¢¡Cµo¥ÍAdam-Stokes¯g­Ôªº¦³5¨Ò¡Cµo¥Í¤ß«Ç©Ê¤ß·i¹L³t©Î¤ß«ÇŸ°Êªº¦³4¨Ò¡A¦û33.3¢H¡A¤ñµL§¹¥þ©Ð«Ç¶Ç¾Éªýº¢¯f¤H¤§14¢H¬°°ª¡C¤U¾À¤ß¦Ù±ð¶ë¯f¤H§¹¥þ©Ð«Ç¶Ç¾Éªýº¢¤§µo¥Í¤Î«ì´_¬O±Ä¶¥¬q¤è¦¡¡A¤j³¡¤À¯f¤H¦b§¹¥þ¶Ç¾Éªýº¢µo¥Í«e¤Î«ì´_¹Lµ{¤¤³£¸g¹L²Ä1«×¤Î²Ä2«×©Ð«Ç¶Ç¾Éªýº¢¡Cµo¥Í²Ä2«×©Ð«Ç¶Ç¾Éªýº¢®É¥D­n¬O¥HMobitz ¢¹«¬¥X²{¡Cµo¥Í²Ä1«×¶Ç¾Éªýº¢®É¡APR¶¡¹j¤j©ó0.24¬íªº¤ñ¤p©ó0.24¬íªÌ¶i¦æ¦Ü²Ä2«×©Î§¹¥þ©Ð«Ç¶Ç¾Éªýº¢ªº¾÷·|¤j¡]66.7¢H¹ï20¢H¡^[33]¡C

¦Ü©ó¨Öµo§ôªK¶Ç¾ÉªýÂ_¡]Bundle branch block¡^±`¨£©ó«e¾À±ð¶ë¡A¤×¥H¥k§ôªKªýÂ_¬°µM¡A¥B±`¨Ö¦³¥ª«e§ôªKªýÂ_¡C»\¦]¥ª¤ß«Ç«e¾À¡A¥k§ôªK¤Î¥ª«e¥b§ôªK¬Ò¥Ñ¦P¤@«e¤U¦æ«aª¬°Ê¯ß¨Ñ¾i¡A¬G¦³¦¹¦X¨Öµo¥Í¤§¶É¦V¡C®Ú¾Ú¥x¤jÂå°|¤§³ø§i[33]¥þ³¡104¦W«æ©Ê¤ß¦Ù±ð¶ë±wªÌ¤¤¦³21¦W¦º¤`¡A¦º¤`²v20¢H¡C¦Ó«e¾À¤ß¦Ù±ð¶ë¸s¤¤¨ä¦º¤`²v¬°27¢H¡A¦p¨Öµo¶Ç¾Éªýê«h¦º¤`²v¬°38¢H¡A¦h¦º©ó¥ð§J¡B¤ßŦ°IºÜ¡B©Î¤ß«Ç¤£¾ã«ß¡C¦Ó¨ä¥þ³¡33¦W«æ©Ê¤U¾À±ð¶ë¸s¤¤¶È2¦W¦º¤`¡A¦º¤`²v6¢H¡C¸Ó¬ã¨s¤¤¦UºØ§ôªKªýº¢¤§¥X²{²v¥ç¬O¥H«e¾À±ð¶ë©~¦h¡A¦Ó¥H¥k§ôªKªýº¢¤Î¥ª«e¥b§ôªKªýº¢³Ì¬°±`¨£¡C¦¹ºØ¶Ç¾Éªýº¢¦h©ó«æ©Ê±ð¶ëµo§@«á3¤é¤º¥X²{¡A¬ù2/3©ó¤@¬P´Á¤º®ø¥¢¡A1/3¥Ã¤[¦s¦b¡C¥t¸Ó°|¦b1977¦~¤§³ø§i[34]Åã¥Ü¡G447¨Ò¤ß¦Ù±ð¶ë¤¤¦³96¨Ò°¾°¼¶Ç¾ÉªýÂ_¡]hemiblock¡^¡Aµo¥Í²v21.5¢H¡A85¨Ò¬°¥ª«e°¾°¼¶Ç¾ÉªýÂ_¡A11¨Ò¬°¥ª«á°¾°¼¶Ç¾ÉªýÂ_¡F«áªÌ§¡­Ý¨ã¥k§ôªK¶Ç¾ÉªýÂ_¡A¦Ó«eªÌ¶È1/3¨ã¥k§ôªK¶Ç¾ÉªýÂ_¡F«áªÌ11¨Ò¤¤¦³9¨Òµo¥Í©Ð«Ç¶Ç¾É»Ùê¡]81.8¢H¡^¡A¦³9¨Ò¦º¤`¡]¦º¤`²v81.8¢H¡^¡A¦Ó«eªÌ¦º¤`²v¶È¬°15.4¢H¡F¥X²{ªº®É¶¡³q±`¬°¤ß¦Ù±ð¶ë¤§²Ä¤@¶g¡Aµ´¤j¦h¼Æ²Ä¤@­Ó¤ë¤º¡A¦Ü©ó®ø¥¢ªº®É¶¡¦h¦b²Ä¤@¶g©Î²Ä¤@­Ó¤ë¤º¡AµM¥ç¦³«ùÄò¶W¹L¤@¦~¥H¤WªÌ¡Cªø©°Âå°|©ó1982¦~³ø§i¨ä4¦~8­Ó¤ë¤¤238¨Ò«æ©Ê¤ß¦Ù±ð¶ë¤¤§ôªK©Î¤ÀªK¶Ç¾ÉªýÂ_¡]bundle branch or fascicular block¡^¤§µo¥Í²v¤ÎÁ{§É­«­n©Ê¡A¥ç±o¨ìÃþ¦ü¤§µ²ªG[35]¡C

¢µ¡D¦³Ãö«æ©Ê¤ß¦Ù±ð¶ëªº¨ä¥¦½×¤å
¤@¡B«æ©Ê¤ß¦Ù±ð¶ëªº¤ß­µ¤Î¤ßŦ°Ê§@
¢w°ê¨¾Âå¾Ç¤¤¤ß¤Îºa¥ÁÁ`Âå°|¡A1971¦~´£¥X¡C[36]¬ã¨s40¨Ò«æ©Ê¤ß¦Ù±ð¶ëªÌ¨t¦Cªº¤ß­µ¤Î«e¯Ý¤ßŦ°Ê§@ªº§ïÅÜ¡A35¦ì¦s¬¡ªÌ¤¤¤§20¦ì±µ¨ü°lÂÜ3¦~¡A©Ò¦³±wªÌ¬Ò¦³¤ß©Ð¿á­µ¡]atrialgallop¡^¤Î¤ß¦y¹Ï¡]apex cardiogram¡^¤W¤§¥¨¤jaªi¡A²Ä¤T¤ß­µ¤Î¤ß¦y¹Ï¤W¤§«ùÄò¦¬ÁYªi«h¸û¤Ö¨£¡C­×¥¿¦¬ÁY´Á¡]corrected systolicphase¡^¦b²Ä¤@¶g¦³ÁYµuªº²{¶H¡A­ì¦]¥i¯à¬O¦]¬°«æ©Ê¤ß¦Ù·lÃa©Ò¾É­Pªº¤ß·i¿é¥X¶q´î¤Ö¡C¦Ó¤jÁnªº²Ä¥|¤ß­µ¤Î¥¨¤jaªi¬O¥Ñ©ó¥ª¤ß«ÇÄéª`ªý¤O¤ÎµÎ±i´Á¥½À£¼W°ª¤§¬G¡Cªø´Á°lÂÜ«á²Ä¥|¤ß­µ¤Î¥¨¤jaªi¤´¬O³Ì±`¨£ªº´Ý¾l¼x­Ô¡AÁöµM¤j¦h¼Æ¤§´T«×¬ÒÅܤp¡C¤ßŦ°IºÜ¦b¤ß¦y¹Ï¤W¦³¥¨¤jaªiªº¸û¦h¡C

¤G¡B¤ß«Ç½F¡]postinfarction ventricular aneurysm¡^¤§Á{§É¤Î¦å¬y¤O¾Ç¤§¬ã¨s
¢w¥x¤jÂå°|1978¦~´£¥X¡C[37] 18¦W¸g¥Ñ¥ª¤ß«ÇÄá¼vÃҹ꦳¥ª¤ß«Ç½Fªº¯f¤H¡A¨C¦ì¬Ò¦³¤ßµ±µh©ÎÆ{¦å©Ê¤ß°IºÜ¡A¬°³Ì±`¨£¤§¯gª¬¡C¤ß¹q¹Ï¤è­±¡A11¦W«e¾À±ð¶ë¯f¤H³£¦³«ùÄò©ÊST¸`¬q¤É°ª¡A3¦W«e¾À­Ý¤U¾À±ð¶ë¯f¤H¤¤2¦W¦³ST¸`¬q¤É°ª¡C¥ª«e¯Ý¾Éµ{§erSR«¬©Î¨äÃþ¦ü«¬¡]rSr'©ÎrSR'¡^ªº¶È4¦W¡C¯Ý³¡X¥ú§e²{¤ßŦ§½³¡¿±°_ªÌ¶È4¦W¡C¨ä¥ª¤ß«ÇµÎ±i²×´ÁÀ£¤O¤Î®e¿n¸û¥¿±`¤H°ª¡A¤ßÁY±Æ¦å¶q¡B¤ßÁY®g¥X¤À¶q¤Î¼Ð·Ç¤Æ¤ßÁY¥­§¡®g¥X³t²v¸û¥¿±`¤H§C¡C5¦W±µ¨ü¤ß«Ç½F¤Á°£©ÎÁ·½K¥H¤Î«aª¬°Ê¯ß¶¹D¤â³N¡A¨ä¤¤2¦W¦º¤`¡C13¦W¤º¬ìªvÀøªÌ°lÂÜ¥­§¡27­Ó¤ë¡]2¡ã43­Ó¤ë¡^¡A¦@3¦W¡]23¢H¡^¦º¤`¡A¥i¨£¹w«á»á¬°¤£¨}¡C

¤T¡B¤ß¦Ù±ð¶ë«á¤ß¹q¹Ï¤§´_­ì
¢w¦å¦æ¤O¾Ç¤Î¤ßŦ¦åºÞÄá¼v¤§¬ã¨s¢w¢w¥x¤jÂå°|1986¦~´£¥X¡C[38] ¤ß¦Ù±ð¶ë«á¤ß¹q¹Ï¤§´_­ì¨Ã«D¨u¨£¡C¸Ó³ø§i¦¬¶°14¨Ò¦¹ºØ¯f¨Ò¨Ã»P¥t14¨Ò¤ß¦Ù±ð¶ë³¡¦ì¤Î«aª¬°Ê¯ßÄá¼v©Ò¨£¬Ûªñ¤§¯f¨Ò¬°¹ï·Ó²Õ¡Aµo²{¨ä¦]¤ß¦Ù±ð¶ë¦Ó³y¦¨ªº¥ª¤ß«Çªº¸Ñ­å¾Ç¤W¤Î¥Í²z¾Ç¤WªºÅܤƧ¡¸û¤ß¹q¹Ï¨S¦³«ì´_ªº¯f¤H¬°»´¡A±À´ú¨ä¹w«á¥çÀ³¸û¨Î¡C±ð¶ë«á¦Ü¤ß¹q¹Ï«ì´_¤§´Á¶¡¡Aµu¦Ü3¤é¡Aªø¦Ü14­Ó¤ë¡A¥­§¡4.9¡Ó6.0­Ó¤ë¡A¨ä¤¤¦³6¦ì¯f¤Hµu©ó2¬P´Á¡C¨äªÍ°Ê¯ß·¤À£¡BªÍ°Ê¯ßÀ£¡B¥ª¤ß«Ç¤ßµÎ´Á¥½À£¡A¤Î¥ª¤ß«Ç¾À¹B°Ê²§±`¬Ò¸û»´¡C°¼ªK´`Àô«hµLÅãµÛ®t§O¡C¨ä¤¤¦³2¨Ò©ó¦Aµo¤ß¦Ù±ð¶ë®É¤ß¹q¹Ï¤Ï¦Ó«ì´_¡C

¥|¡B¤ß¦Ù±ð¶ë«á«aª¬°Ê¯ß³y¼v¹Ï¤§ÅܤÆ
¢w¥x¤jÂå°|1986¦~´£¥X¡C[39] ¦^·¹¤ÀªR1977¦~1¤ë¦Ü1985¦~1¤ë174¨Ò«æ©Ê¤ß¦Ù±ð¶ë¤§¯f¨Ò¡A48¨Ò¡]27.6¢H¡^¬°3±ø«aª¬°Ê¯ß¬Ò¦³¯U¯¶¡A61¨Ò¡]35.1¢H¡^¬°2±ø«aª¬°Ê¯ß¯U¯¶¡A63¨Ò¡]36.2¢H¡^¬°1±ø¯U¯¶¡A¥t¦³2¨Ò¡]1.1¢H¡^¥¼µo²{¯U¯¶¡C¥H¦U«aª¬°Ê¯ß¦Ó¨¥¡A¥ª«e­°¤ä¦@151¨Ò¡]86.8¢H¡^µo¥Í¯U¯¶¡A¥k«aª¬°Ê¯ß¦³61¨Ò¡]35.1¢H¡^¡A¥ª°j±Û°Ê¯ß¦³11¨Ò¡]6.3¢H¡^¡C«aª¬°Ê¯ß§¹¥þªý¶ë¤§µo¥Í²v¥H«æ©Ê¤ß¦Ù±ð¶ëµo¥Í«á8¤p®É¤§¤º°µ«aª¬°Ê¯ß³y¼v¤§¯f¤H²Õ³Ì°ª¡A¦û81.3¢H¡AµM«á³vº¥¤U­°¡A¦Ü1¦~¥H«á¤~°µ«aª¬°Ê¯ß³y¼v¤§¯f¤H²Õ¤Ï¦Ó¦^¤É¡C±ð¶ë¬ÛÃö°Ê¯ß¨S¦³§¹¥þªý¶ë¤§¯f¤H¡A¦b¦U²Õ¤¤¸Ó¦åºÞ¤§¯U¯¶µ{«×³£¬OÄY­«ªº¡C¦h±ø«aª¬°Ê¯ß¯e¯f¸û©öµo©ó¦~ÄÖ¸û¤j¡B¥ª¤ß«Ç¤U¾À±ð¶ë¤Î¤w¦³¤ß¦Ù±ð¶ë¯f¥v¤§¯f¤H¡A¥ª¤ß«Ç°IºÜ¡B±ð¶ë«á¯Ýµh¡B¤ß©Ð¤ß«Ç¶Ç¾É»Ùê¬O¨ä«ü¼x¡C¤ß«Ç¦­´Á¦¬ÁY¸û±`¨£©ó±ð¶ë¬ÛÃö°Ê¯ß¬°¥ª«e­°¤ä°Ê¯ß¤§¯f¤H¡A¦Ó¤ß©Ð¤ß«Ç¶Ç¾É»Ùê©M±ð¶ë«á¯Ýµh«h©ö¨£©ó¥k«aª¬°Ê¯ß±ð¶ëªÌ¡C°lÂܦÜ1985¦~4¤ë©³¡A¦@µo¥Í24¨Ò¤ß¦]©Ê¦º¤`¡A133¨Ò¦s¬¡¡A12¨ÒµLªkÁpµ¸¡A6¨Ò«D¤ß¦]©Ê¦º¤`¡C3±ø«aª¬°Ê¯ß³£¦³¯U¯¶¬°ªø´Á¦s¬¡²v¤£¨}¤§«ü¼x¡C

¤­¡B¤ß¦Ù±ð¶ë¦X¨Ö¥ª¤ß«Ç½F¯f¤H¤§¤ß«ß¤£¾ã
¢w°ê®õÂå°|1991¦~´£¥X[40]¡C»`¶°30¦ì¦³¤ß¦Ù±ð¶ë¦X¨Ö¤ß«Ç½Fªº¯f¤H¤§24¤p®ÉÀN¤ó¤ß¹q¹ÏªºÀˬd¡Aµo²{¨ä¤W¤ß«Ç©Ê¤Î¤ß«Ç©Ê¤ß«ß¤£¾ãªº·§²v¦³©úÅ㪺¼W¥[¡C³o©M«aª¬°Ê¯ß¯e¯fªºÄY­«©Ê¥H¤Î¥ª¤ß«Ç¥\¯àªº¦nÃa¨Ã¨S¦³©úÅ㪺Ãö«Y¡F¥ª¤ß«Ç½F¥i¯à¬O»¤µo¤ß¦Ù±ð¶ë«áµo¥Í¤ß«ß¤£¾ã·¥­«­n¥B¿W¥ßªº¦]¯À¡C

¤»¡B¥H¦A­«²Õ²Õ´­M¼ß¯À­ì¿E¬¡¯À(recombinant tissue plasminogen activator)ªvÀø¤ß¦Ù±ð¶ë¤§±wªÌ²£¥Íªº¤ß«ß¤£¾ã
¢w1991¦~ºa¥ÁÁ`Âå°|´£¥X[41]¡C22¨Ò«æ©Ê¤ß¦Ù±ð¶ë±wªÌ¤¤¦³19¨Ò¸g¤ß¾ÉºÞÀˬdÃҹ꦳ªý¶ë¦åºÞ¦AÄé¬yªº±¡§Î¡A¨ä¤¤¤ß«ß¤£¾ãªºµo¥Í²v¦bªvÀø«á¬°84.2¢H¡C¤ß«Ç¦­´Á¦¬ÁYªºµo¥Í²v³Ì°ª¡A¬°73.6¢H¡A¨ä¦¸¬°¤ß«Ç¤ß«ß¹L³t¡A¬°47.3¢H¡A¥[³t©Ê¤ß«Ç¤ß«ß¶È¬°31.5¢H¡C¦bµo¥Í®É¾÷¤W±©¦³¥[³t©Ê¤ß«Ç¤ß«ß¦bªvÀø«á²Ä¤@¤p®É¤§¤º¦³¯S®íªº°ª®pµo¥Í²v¡A¥B¤@­Ó¥b¤p®É¤§«á¬Ò¤£¦A¥X²{¡A¥i¯à¬O¤ß¦Ù¦AÄé¬y¤§ªí¼x¡A¦ý¨äµo¥Í²v¶È¤T¤À¤§¤@¥ª¥k¥BÁ{§É¤Wªº»ù­È©|«Ýµû¦ô¡C©Ò¦³¦AÄé¬y¤§¤ß«ß¤£¾ãÁ{§É¹Lµ{¬Ò¬°¨}©Ê¡A¤£»Ý¯S§OªvÀø¡C

¤C¡B¤ßŦ¶W­µªi¦Ç¥Õ¦â½Õ¦b«æ©Ê¤ß¦Ù±ð¶ë¯f¤H¤§¤@¨t¦C¤ÀªR
¢wºa¥ÁÁ`Âå°|1991¦~´£¥X[42]¡C¹ï16¦ì¯f¤H°µ¤FÂù­±¤ßŦ¶W­µªi¤§Àˬd¡A¤À§O¦b±ð¶ëµo§@«á8¤p®É¤º¡A²Ä16¡B24¡B36¡B48¤p®É¡A©M²Ä3¡B7¡B42¡B60¤Ñ±µ¨ü¤@¨t¦C¤§Àˬd¡Aµo²{¤ß¦Ù±ð¶ë«á¥­§¡¦Ç¥Õ¦â½Õ¦³ÀH®É¶¡³vº¥¼W¥[ªºÁͶաA¦Ó¥B³¯Â©ʤߦٱð¶ëªº¥­§¡¦Ç¥Õ¦â¤ñ¦­´Á¤§¤ß¦Ù±ð¦³·N¸qªº¼W¥[¡C

¥|¡B ¹B°Ê¤ß¹q¹Ï¤§¬ÛÃö¬ã¨s
¹B°Ê¤ß¹q¹ÏÁ{§É¤W±`¥Îªº¥D­n¦³MasterÂù¶¥¦¡¹B°Ê¤ß¹q¹Ï¸ÕÅç¤Î¼i±a¦¡¹B°Ê¤ß¹q¹Ï¨âÃþ¡A¬°«D«Iŧ©ÊÀˬd¡A¤£¶È¦bÀ°§U¶EÂ_¤W¦³¨ä»ù­È¡A¹ï«aª¬°Ê¯ß¯f¤H¯e¯fÄY­««×¡B¹w«á¡A¤ÎÀø®Ä¤§µû¦ô¬Ò¬Æ¦³§U¯q¡A¤À­z©ó¤U¤å¡C
¡@ ¢°¡DÂù¶¥¦¡¹B°Ê¤ß¹q¹Ï¡]double master two-step exercise test¡^
¥x¤jÂå°|1960¦~¤ñ¸û50¦ìÂå¾Ç¨t¨k¾Ç¥Í¤Î5¦ì¯u¥¿¦³«aª¬°Ê¯ß¯e¯f±wªÌµo²{®Ú¾ÚMasterªº­ì¼Ð·Ç¡A°²¶§©Ê²v©ó³æ¤@¸ÕÅ笰14¢H¡BÂù¦¸¸ÕÅ笰6¢H¡C»P¯u¶§©Ê±wªÌ¤§®t§O¬°ST¬q¤U­°¸û»´©Î¥u¦³³¡¤ÀST¬q¤U­°¡A³s±µ³BST¬q(junction)¤U­°¡A¤Î¤U­°®É¶¡¤Ö©ó2¤ÀÄÁ¡C¸Ó¤å³¹§@ªÌ«ØÄ³¤§¶EÂ_¼Ð·Ç¬°¡GST¬q¤U­°¶W¹LPR¬q0.5mm¥H¤W¤§¤ô¥­«¬©Î¤U©Y«¬¡A©ÎST¬q³s±µ³B¤U­°1.0mm¥H¤W¥BµL¤ß·i¹L³t[43]¡C

¥x¤jÂå°|©ó1976¦~³ø§i¦Û1973¦Ü1974¦~¦b¤TªÛ¶m¤Î¥x¥_¥«©Ò°µ1727¤H¤§Âù¶¥¦¡¹B°Ê¤ß¹q¹Ï¸ÕÅç¡Aµo²{¤£½×¨k¤k¨ä¶§©Ê²v¬ÒÀH¦~ÄÖ¤§¼W¥[¦Ó¼W°ª¡C¤k©Ê¤§¶§©Ê²v¬ù¬°¨k©Ê¤§¤T­¿¡C¶§©ÊªÌ¤ßÁY¤Î¤ßµÎÀ£¸û³±©ÊªÌ°ª¡C¨ä±Ó·P«×¨k©Ê¤ñ¤k©Ê§C¡A¦ýÀH¦~ÄÖ¦Ó¼W¥[¡C¦Ü©ó¯S®í«×¡]specificity¡^«h¨k©Ê¸û¤k©Ê¬°°ª[44]¡C

1977¦~¥x¤jÂå°|µoªí¹ï138¦W¥D¶D¯Ý´eªÌ¬I¥HÂù¶¥¦¡¹B°Ê¤ß¹q¹Ï¤Î«aª¬°Ê¯ßÄá¼v¡A¨ä¤¤95¦W¦³¦Ü¤Ö¤@±ø«aª¬°Ê¯ß50¢H¥H¤W¤§ªý¶ë¡A¥t43¦W«h¬°¥¿±`¸s¡C¦p±Ä¥ÎST¸`¬q¤§¯Ê®ñ©Ê¤U­°©Î¤Wª@0.5mm¥H¤W¬°¶§©Ê¹B°Ê¸ÕÅ礧«ü¼Ð¡A«h95¦W«aª¬°Ê¯ß±wªÌ¤¤35¦W¡]37¢H¡^¥X²{³±©Ê¤ÏÀ³¡]°°³±©Ê¤ÏÀ³¡^¡A¦Ó43¦W¥¿±`¸s¤¤5¦W¡]12¢H¡^¥X²{¶§©Ê¤ÏÀ³¡]°°¶§©Ê¤ÏÀ³¡^¡C°°¶§©Ê¤ÏÀ³À³¥H¤k©Ê¸û¬°±`¨£¡]¤k©Ê22¢H¡A¨k©Ê9¢H¡^¡C¦Ü©óMaster 1968¦~©Ò´£¤§¶§©Ê¹B°Ê¤ß¹q¹ÏÅܤơA°£¤W­z¤§ST¸`¬q¤§¯Ê®ñ©Ê§C¤U¡]§C³´0.5mm¥B«ùÄò0.08¬í¥H¤W¡^¥~¡A©|¥]¬ATªi¤§­Ë¸m¡A©ÎJ§Î¤§§C¤U¦ñÀHQX/QT¡Ù0.50¥BQT ratio¡Ù1.08µ¥ÅܤơA«á¤GªÌ¤§¥¿½T¶EÂ_²v¶È¬°75¢H¤Î57¢H¡A¦Ó«eªÌ«h¬°92¢H¡C¦pST¸`¬q¤U­°¶W¹L1.0mm¥H¤W®É¡A¥þµL°°¶§©Ê¯f¨Ò¥X²{¡A¦ý°°³±©Ê°ª¹F62¢H¡C§C¤U2.0mm¥H¤W®É¡]8¨Ò¡^¨ä«aª¬°Ê¯ß³£¦³­««×ªý¶ë¡]ªý¶ë¤À¼Æ10¤À¥H¤W¡^[45]¡C

¦Ü©ó¨ä§PŪ­Ó§O®t²§©Ê¦p¦ó¡H®Ú¾Ú1978¦~°ê¤º¼Æ®a¤j«¬Âå°|¤§Áp¦X¬ã¨s¡A¥Ñ5­ÓÂå°|ªº¤ßŦ±M¬ìÂå®v¡A«ö·ÓMaster©Ò­qªº¶§©Ê¼Ð·Ç¡]¦pªí4¡^¡A§PŪ861¦ì°·±dµL¯gª¬ªÌ©Ò§@¤§¹B°Ê¤ß¹q¹Ï¡Aµ²ªG­Ó¤H§PŪ¤§®t²§©Ê¬Û·íÅãµÛ¡A¦pªí5¡B6¡B7¤Î8 [46]¡C

¥x¤j¤Î°ê®õÂå°|¦b1981¦~µoªí¥x¥_¥«¤Î¤TªÛ¶m1701¦ì¥Á²³¤§Âù¶¥¦¡¹B°Ê¤ß¹q¹Ï¡A¨ä¤¤207¦ì¡]12.2¢H¡^¬°¶§©Ê¡A¦Ó·í¤¤¦³168¦ì¡]81.2¢H¡^¤§¥ð®§®É¤ß¹q¹Ï¬°²§±`¡C¨ä¤¤¸û¦³Ãö¤§¥ð®§®É¹B°Ê¤ß¹q¹Ï²§±`¬°¥ª¯Ý°ªRªi¡B­Ë¦VTªi¡BSTªi¬q¤U­°¡B«ó¥­©ÎÂù¦VTªi¡B­t¦VUªiµ¥¡]P<0.005¡^¡C¦]¦¹¶§©ÊÂù¶¥¦¡¹B°Ê¤ß¹q¹Ï©ó¥ð®§®É¦³²§±`¤ß¹q¹Ï®É§PŪ¶·¤p¤ß[47]¡C

¢±¡D¼i±a¦¡¹B°Ê¤ß¹q¹Ï¡]treadmill exercise test¡^
¼i±a¦¡¹B°Ê¤ß¹q¹Ï¬°¶EÂ_ºÃ¦ü«aª¬°Ê¯ß±wªÌªº­«­n¶EÂ_¤èªk¡Aºa¥ÁÁ`Âå°|©ó1977¦~µoªí63¨ÒºÃ¦ü«aª¬°Ê¯ß¯e¯f±wªÌªº¼i±a¦¡¹B°Ê¤ß¹q¹Ï»P«aª¬°Ê¯ßÄá¼vªº¬ã¨sµo²{¨ä±Ó·P«×¡]sensitivity¡^¬°86¢H¡A¯S²§«×¡]specificity¡^¬°73¢H¡C73¢Hªº°²¶§©Ê±wªÌ¦³°ª¦åÀ£¡C¥ª«aª¬°Ê¯ß¥D·F³¡¤Î¤T±ø«aª¬°Ê¯ß¯e¯f±wªÌªº¯S¦â¬O¹B°Ê«ù¤[©Ê¤p©ó3¤ÀÄÁ¡B¤U¶É¦¡ST¤U­°¤ÏÀ³¡BSTªi¬q¤U­°µ¥©ó©Î¤j©ó3mm¥B³q±`¬O¹B°Ê¤¤§Y¶}©l¤U­°¡C°²¶§©Ê¤ÏÀ³ªº¯S¦â¬O¹B°Ê®É¶¡¤j©ó6¤ÀÄÁ¡B¤W±×¦¡ST¤U­°¤ÏÀ³¥B¤p©ó0.9mm¥B¤j³¡¤À¹B°Ê«á¤~¶}©l¤U­°[48]¡C

ªø©°Âå°|1981¦~µoªí57¦ì±µ¨ü¼i±a¦¡¹B°Ê¤ß¹q¹Ï¤Î«aª¬°Ê¯ßÄá¼vÀˬd±wªÌªº¬ã¨sµo²{¡GÀRºA¤ß¹q¹Ï¥¿±`ªÌ¤§±Ó·P«×¬°86¢H¡A¯S²§«×¬°50¢H¡FÀRºA¤ß¹q¹Ï²§±`ªÌ¤§±Ó·P«×¬°90¢H¡A¯S²§«×¬°44¢H¡C13­Ó¯f¤H¹B°Ê®É²£¥Í¯Ýµh¡A¨ä¤¤¤G¤HST¬qµL²§±`ÅܤơC¹B°Ê®É¦³¯ÝµhÅãµÛ¼W¥[¶EÂ_ªº±Ó·P«×¡A¦P®É¨ä«aª¬°Ê¯ß¯fÅܸûÄY­«¡C»´«×¹B°Ê´N¦³¯Ýµh¤Î2mm¥H¤WªºST¬q¤U­°ªÌ5¦W¤¤¦³4¦W¬°¥ª«aª¬°Ê¯ß¥D·F©Î¥ª«e­°¤äªñºÝ¯e¯f¡C¹B°Ê®É¥­©Z«¬¤§¦åÀ£¤ÏÀ³¡A¨£¤_3¦WÅãµÛ«aª¬°Ê¯ß¯e±w¤Î5¦W¡]4¦W¬°¤k©Ê¡^¤£ÅãµÛ«aª¬°Ê¯ß¯e±w¡C¯Ýµh©Î¹B°Ê®É¦åÀ£¤£¤É¦b¤k©Ê¬°¸û¤£¥i¾aªº¨Ì¾Ú[49]¡C

ªø©°Âå°|¦b1984¦~¹ï89¦W±wªÌªºÃþ¦ü¬ã¨s¥çµo²{¦­´Á¡]BruceStage ¢¹¡^¥X²{STÅܤơA¯S§O¬O¤j©ó2mmªÌ¡A±`¨£©ó¸ûÄY­«ªº±wªÌ¢w¢w¥ª«aª¬°Ê¯ß¥DªK¡B¥ª«e­°ªKªñºÝ¡A©Î¤T±ø¦åºÞ¯e¯f[50]¡C

°ª¦åÀ£±wªÌ¼i±a¦¡¹B°Ê¤ß¹q¹Ï¶§©Ê²v®Ú¾Ú°ê¨¾Âå¾Ç°|1967¦~ªº³ø§i¬°24¢H¡A¤ñ¦åÀ£¥¿±`ªÌ¤§9¢HÅãµÛ¸û°ª[51]¡C

°ê¨¾Âå¾Ç°|¤ÎºaÁ`¦b1967¦~¤Î1975¦~µoªí942­Ó¤¤¦~¤¤°ê¤Hªº¼i±a¦¡¹B°Ê¤ß¹q¹Ïµo²{8¢Hªº¶§©Ê²v¡C7¦~«á¤§°lÂÜÀˬdµo²{¤ßŦ¦åºÞ¯e¯fªº­P¯f²v¡]morbidity¡^¦b¨S¦³°ª¦åÀ£¥BµLST§C¤UÅܤƪº¬°2.3¢H¡A¦Ó¶ÈST§C¤UªÌ¬°5.7¢H¡A¶È°ª¦åÀ£ªÌ¬°11.9¢H¡A¨âªÌ³£¦³ªº¬°25.0¢H¡C¥i¨£°ª¦åÀ£ªº­«­n©Ê¶W¹L¹B°Ê¤ß¹q¹Ï¤WªºST¤U­°¡A¦ý¨âªÌ¦³¬Û¥[¦¨ªº®ÄªG[52,53]¡C¸Ó°|¦b1969¦~µoªí1346¦ì¤¤¦~¥x¥_¥«¥Áªº¼i±a¦¡¹B°Ê¤ß¹q¹Ïµo²{¨ä¶§©Ê²v¬°7¢H¡A¥B»P¦~ÄÖ¡B¦åÀ£¡B¬Û¹ïÅé­«¤Î¤@¨Ç¥ð®§®É¤ß¹q¹Ï¤§²§±`¬ÛÃö[54]¡C

¼i±a¦¡¹B°Ê¤ß¹q¹ÏÁöµM¤j­P¬O«D±`¦w¥þªºÀˬd¡A¦ý¥ç°¸¦Ó¦³ÄY­«ªº¨Öµo¯g²£¥Í¡C¥x¤j¤ÎºaÁ`¦U¦b1979¦~[55]¤Î1980[56]¦U³ø§i¤@¨Ò¦b¨ü¸Õ¤¤²£¥Í¤ß«ÇŸ§Ý¡]ventricular fibrillation¡^¤§¯f¨Ò¡AÁöµM¬Ò¦³ÅåµLÀI¦¨¥\±Ï¦^¡A¦ý¥çªí¥Ü¤£¥i¤£·V¡C

¦Ü©ó¶§©Êªº¶EÂ_·Ç«h°£¤F¶Ç²ÎªºSTªiÅܤơB¯gª¬¡A¤Î¦åÀ£ªºÅܤƥ~¡A¹B°Ê¤¤ªºRªi°ª«×¼W¥[¥ç¦³¤H´£¤Î¡Cªø©°Âå°|¦b1984¦~´£¥X¤@½g±´°Q¦¹¶EÂ_·Ç«hªº¬ã¨s³ø§i¡Aµo²{¹ï­««×«aª¬°Ê¯ß±wªÌ¤§±Ó·P«×¦bV5¬°27¡ã43¢H¡A¦baVF¬°38¡ã52¢H¡F¨ä¯S²§«×¦bV5¬°64¡ã78¢H¡A¦baVF¬°70¡ã84¢H¡F¶EÂ_®Ä²v¦bV5¬°49¡ã55¢H¡A¦baVF¬°49¡ã57¢H¡C¦Ó¥HST¬q¬°¶EÂ_®Ú¾Ú¤§±Ó·P«×¡B¯S²§«×¤Î®Ä²v«h¤À§O¬°89¢H¡B47¢H¤Î64¢H[57]¡C

¤­¡B ¦V¶q¤ß¹q¹Ï¡]vectorcardiographic study¡^¤ÎÅéªí­±¤ß¹q¹Ï¡]body surface potential mapping¡^¤§¬ÛÃö¬ã¨s
¡@ ¦³Ãö¦V¶q¤ß¹q¹Ï¤ÎÅéªí­±¤ß¹q¹Ï©ó«aª¬°Ê¯ß¤ßŦ¯fªº¬ã¨s°ê¤º¤§¤åÄm¦h¬°¥x¤jÂå°|©Òµoªí¡A¯÷¤À­z©ó¤U¤å¡C

¥HÀRºA¦¡¦V¶q¤ß¹q¹Ï¶EÂ_¯Ê¦å©Ê¤ßŦ¯f¡A¥x¤jÂå°|©ó1977¦~µoªí¨Ì¾Ú80¦W¨å«¬¯U¤ß¯g±wªÌ¤Î40¦W¥¿±`¤H©Ò°µ¤§¬ã¨s³ø§i«ü¥X¥i¨Ñ¶EÂ_¤§·Ç¾Ú¦p¤U[58]¡G

1. ¥ô¦ó§ë¼v­±¤§TÀô´yµe³t«×©ÎTÀô§Îª¬¤§²§±`¡C
2. ¥ª¥Úª¬­±©Î¤ô¥­­±¤§TÀô´yµe¤è¦V¤§²§±`¡C
3. TÀô§ë¼v©ó«e¤U¥ª¤è¥H¥~¤§°Ï°ì¡C
4. TÀô¨¤¦b«eÃB­±¶W¥X80¢X¦Ü60¢X½d³ò¡A©Î¥ª¥Úª¬­±¶W¥X90¢X¦Ü167¢X½d³ò¡A©Î¤ô¥­­±11¢X¦Ü65¢X½d³ò¡C
5. TÀô¤§ªø¡þ¼e¤ñ¡]L/W¡^¤p©ó2.6¡]¤£½×¥ßÅé¤ñ­È©Î¥­­±¤ñ­È¡^¡A¦ý¥ª¥Úª¬­±°£¥~¡C
6. ST¦V¶q§ë¼v©ó¤U¦C¤§¥ô¤@¦ì¸m¡G«e¤¤¥k¤è¡B«e¤W¥k¤è¡B«e¤W¤¤¤è¡A©Î«á¤U¥k¤è¡C
7. ST¦V¶q¦b«eÃB­±¬O0.1mV¥H¤W¡A©Î¤ô¥­­±0.15mV¥H¤W¡C
8. ST¦V¶q¤§¤è¦V¦b«eÃB­±¶W¥X354¢X¦Ü98¢X½d³ò¡A©Î¥ª¥Úª¬­±¶W¥X90¢X¦Ü188¢X½d³ò¡A©Î¤ô¥­­±¶W¥X50¢X¦Ü96¢X½d³ò¡C
9. ¥ô¦ó¤@¥­­±¤§QRS/T¤ñ­È¤j©ó7¥H¤W¡C
10. QRS-T§¨¨¤¦b«eÃB­±¬O50¢X¥H¤W¡A©Î¤ô¥­­±¬O100¢X¥H¤W¡C

¥H¹B°Ê¸ÕÅ礧¦V¶q¤ß¹q¹Ï¶EÂ_¯Ê¦å©Ê¤ßŦ¯f¡A¥x¤jÂå°|¥H¦P¤W½g¤§¯f¤H°µMaster¤ó¹B°Ê¸ÕÅ窺¦V¶q¤ß¹q¹Ï©Ò±o¤§¶§©Ê¶EÂ_·Ç¾Ú¦p¤U¡G¥Ò¡^¥D­n·Ç¾Ú¡G1) TÀô§Îª¬¤§§ïÅÜ¡C2 )TÀô´yµe¤è¦V¤§§ïÅÜ¡C3) TÀô´yµe³t«×¤§§ïÅÜ¡C4) ST¦V¶q¤§§ïÅÜ¡A©ó«eÃB­±¤j©ó15¢X¡A©Î©ó¥ª¥Úª¬­±©Î¤ô¥­­±¤j©ó20¢XªÌ¡C5) ³Ì¤jT¦V¶q¤è¦V¤§§ïÅÜ¡A©ó«eÃB­±¤j©ó15¢X¡A©Î©ó¥ª¥Úª¬­±©Î¤ô¥­­±¤j©ó25¢X¡C6) ¥ô¤@§ë¼v­±¤§ST¦V¶qªº¼W¥[¤j©ó0.04mV¡C7) QRS-T§¨¨¤¤§§ïÅܦb«eÃB­±¤j©ó15¢X¡A©Î©ó¥ª¥Úª¬­±©Î¤ô¥­­±¤j©ó25¢X¡C8) TÀô¤§ªø¹ï¼e¡]L/W¡^¤ñ©ó¥ª¥Úª¬­±©Î¤ô¥­­±¤j©ó3¡C9) TÀô³Ì¤j¼e«×¤§¼W¥[¤j©ó0.2¡]mV¡^¡C¤A¡^¦¸­n·Ç¾Ú¡G1) ST¦V¶q¤§¤è¦Vªº§ïÅÜ¡A¦b«eÃB­±¤j©ó8¢X¡A©Î©ó¥ª¥Úª¬­±©Î¤ô¥­­±¤j©ó12¢X¡C2) ST¦V¶q¤j¤p¤§§ïÅܤj©ó0.03¡]mV¡^¡C3) ³Ì¤jT¦V¶q¤§¤è¦Vªº§ïÅܦb«eÃB­±¤j©ó6¢X¡A©Î©ó¥ª¥Úª¬­±¤j©ó12¢X¡A©Î¤ô¥­­±¤j©ó8¢X¡C4) TÀô³Ì¤j¼e«×¤§¼W¥[¤j©ó0.04¡]mV¡^¡C5) QRS-T§¨¨¤¦b«eÃB­±¤j©ó6¢X¡A©Î©ó¥ª¥Úª¬­±¤j©ó12¢X¡A©Î¤ô¥­­±¤j©ó8¢X¡C6) ¹B°Ê«áTÀô¤§ªÅ¶¡ªºªø¹ï¼e¡]spacial L/W¡^¤ñ¤p©ó2.6¡C7) ³Ì¤jQRS¦V¶q¹ï³Ì¤jT¦V¶q¡]QRS/T¡^¤§¤ñ§ïÅܤj©ó2¡C

¥D­n·Ç¾Ú¥uµo¥Í©ó¯U¤ß¯g±wªÌ¡C¦Ü©ó¦¸­n·Ç¾Ú¡A¯U¤ß¯g¸s¤§©Ò¦³±wªÌ§¡¦³¥|¶µ¥H¤W¡A¦Ó¥¿±`¹ï·Ó¸s¤¤¥u¦³2.5¢H¨ã¦³Ãþ¦ü±¡§Î[59]¡C1978¦~¥x¤j³ø§iÀRºA¦¡¦V¶q¤ß¹q¹Ï¹ï¯Ê¦å©Ê¤ßŦ¯f¤§ÄY­«µ{«×ªºµû¦ô¡Aµo²{«aª¬°Ê¯ß¤À¼Æ¡]coronary artery scores¡^»P¤U¦C¤§ÀRºA¦¡¦V¶q¤ß¹q¹Ï¤§©Ò¨£¦³±K¤ÁªºÃö«Y¡GTÀô´yµe¤§¤è¦V©Î³t«×¡CTÀô¤§²§±`§Îª¬©Î´yµe¤è¦V¤§§ë¼v­±ªº¼Æ¥Ø¡C³Ì¤jT¦V¶q§ë¼v¤§¤è¦V¡CST¦V¶q§ë¼v¤§¤è¦V¡C³Ì¤jT¦V¶q¤§¤è¦V¡CST¦V¶q¤§¤è¦V¡CST¦V¶q¤§¤j¤p¡C³Ì¤jQRS¦V¶q¹ï³Ì¤jT¦V¶q¡]QRS/T¡^¤§¤ñ­È¡CQRS-T§¨¨¤¡C¦¹¥~¡A«aª¬°Ê¯ß¨ü«I¼Æ¥Ø»P¤U­z¤§ÀRºA¦¡¦V¶q¤ß¹q¹Ï¤§©Ò¨£¶¡¥ç¦³±K¤ÁªºÃö«Y¡GTÀô¤§²§±`§Îª¬©Î´yµe¤è¦V¤§§ë¼v­±ªº¼Æ¥Ø¡C³Ì¤jT¦V¶q¤§¤è¦V¡CST¦V¶q¤§¤è¦V¡CST¦V¶q¤§¤j¤p¡CQRS-T§¨¨¤[60]¡C

¥x¤j1978¦~µoªí¦V¶q¤ß¹q¹Ï¹ï©ó¯Ê¦å©Ê¤ßŦ¯f±w¤§¹B°Ê­@¤Oªºµû¦ô¬ã¨sÅã¥Ü¹B°Ê¦¡¦V¶q¤ß¹q¹ÏÀu©ó¹B°Ê¦¡¥­­±¤ß¹q¹Ï¡A¥B¨ä°ª«×±Ó·P©Ê¨ÏMaster¤ó¹B°Ê´úÅ礧¹B°Ê¶q¨¬¥H»¤¾É¦³¯Ê¦å©Ê¤ßŦ¯f¤§±wªÌ²£¥Í¦V¶q¤ß¹q¹ÏªºÅܤơA¦p¦¹±N¥iÁ×§K¦]»Ý¸û¤j¹B°Ê¶q¥H¤Þµo¯Ê¦åÅܤƦӲ£¥Íªº¥i¯à¦MÀI©Ê¡C¤×¦³¶iªÌ¡A¹B°Ê¦¡¦V¶q¤ß¹q¹Ï¯à´£¨Ñ¤U¦C¸ê®Æ¥H§@¬°¯Ê¦å©Ê¤ßŦ¯f±wªº¹B°Ê­@¤O¤§«ÈÆ[¦Ó¹ê¥Îªºµû¦ô¡G§Y¦h¶¥¬q¹B°Ê´úÅ礧¹B°Ê¶q¡F¹B°Ê«á¤ß¦Ù¯Ê¦åªº¦V¶q¤ß¹q¹ÏÅܤƤ§«ùÄò®É¶¡¡F¨äÅܤƤ§½d³ò¡F¤Î¨äÅܤƤ§¶µ¥Ø¤Î¨äµ{«×[61]¡C

¥x¤j©ó1984¦~³ø§i60¦W«aª¬°Ê¯ß¯e¯f±wªÌªº³Ì¤jQRS¦V¶q¹ïMaster¤ó¹B°Ê´úÅ窺¤ÏÀ³¡Aµo²{¦¹µ¥±wªÌ¦b¹B°Ê«á³Ì¤jQRS¦V¶qªº¤è¦V¤Î¤j¤p§¡¦³§ïÅÜ¡CÃö©ó³Ì¤jQRS¦V¶qªº¤j¤pÅܤơA´î¤ÖªÌ¦b«eÃB­±¸û¦h¡A¦Ó¦b¥ª¥Úª¬­±¤Î¤ô¥­­±¸û¤Ö¡A³oºØ©Ò¨£¦b¥ª¥Úª¬­±¯S§O©úÅã¡]P<0.001¡^¡A¤×¨ä³oºØÅܤƦb¦³¤T±ø«aª¬°Ê¯ß¯f±wªÌ¤Î°ª«aª¬°Ê¯ß¤À¼Æ±wªÌ§ó¬°©úÅã¡C¦Ü©ó³Ì¤jQRS¦V¶q§¨¨¤ªºÅܤơA¼W¤jªÌ¦b«eÃB­±¤Î¥ª¥Úª¬­±¸û¦h¡A¦ý¦b¤ô¥­­±¸û¤Ö¡A³oºØ©Ò¨£¥H¦b«eÃB­±¤Î¤ô¥­­±¸û¬°©úÅã¡]P<0.001¡^¡A³oºØÅܤƤ]¥H¦b¦³¤T±ø«aª¬°Ê¯ß¯e¯f¤Î°ª«aª¬°Ê¯ß¤À¼Æ¤§±wªÌ§ó¬°©úÅã¡C¯e¯f¤§«aª¬°Ê¯ßªº¼Æ¥Ø»P³Ì¤jQRS¦V¶q¤§¤è¦V¤Î¤j¤pªºÅܤƦ³±K¤ÁªºÃö«Y¡]P<0.05¡^¡C¦³¯f¤§«aª¬°Ê¯ßªº¼Æ¥Ø·U¦h¡A¹B°Ê«á¤§³Ì¤jQRS¦V¶q´î¤Ö©Î³Ì¤jQRS¦V¶q¥k²¾ªº¯f¨Ò¤]·U¦h¡C¦P¼Ëªº¡A«aª¬°Ê¯ß¤À¼Æ»P³Ì¤jQRS¦V¶q¤§¤j¤p¤Î¤è¦VªºÅܤƤ]¦³Ãþ¦üªºÃö«Y¡AµM«o¥¼¹F²Î­p¾Ç¤W¦³·N¸q¤§µ{«×¡]0.05<P<0.1¡^¡C¦]¦¹¹B°Ê«á³Ì¤jQRS¦V¶qÅܤp©Î¥k²¾¥i¯à¬O¦³¤T±ø«aª¬°Ê¯ß©Î°ª«aª¬°Ê¯ß¤À¼Æªº«ü¼Ð[62]¡C

¦Ü©óÅéªí­±¹q¦ì¹Ï¦b«aª¬°Ê¯ß¯f±wªÌªºÁ{§ÉÀ³¥Î¡A¥x¤jÂå°|1988¦~µoªí[63] 98¨Ò¨ã¯U¤ß¯g¤Î«aª¬°Ê¯ß¯fªº±wªÌªº¬ã¨sµo²{¡G¦b¤ß«Ç¥h·¥¤Æ¹Lµ{¤¤¡A¦³97.9¢Hªº±wªÌ¤§Åéªí­±¹q¦ì¹ÏÅã¥Ü¦b«e¯Ý¦³²§±`­t¹q¦ì¤Î·¥¤p¹q¦ìªº¤À§G¡A¦Ó¤ß¹q¹Ï¤Î¦V¶q¤ß¹q¹Ï¯à´ú¨ì³oºØ¤ßŦ¹q¤O®ø¥¢ªº±Ó·P«×¤À§O¬°58.2¢H¤Î84.7¢H¡A²§±`­t¹q¦ì¤§¤À§G¦b¥k«aª¬°Ê¯ß±wªÌ¥D­n¥X²{©ó«e¯Ý¤§¤¤¥¡©Î¥k°¼¡A¦b¥ª°j±ÛªK«aª¬°Ê¯ß±wªÌ¥D­n¥X²{©ó«e¯Ý¤§¥ª¤W³¡¡A¦b¥ª«e­°ªK«aª¬°Ê¯ß¯f±wªÌ¥D­n¥X²{©ó«e¯Ý¤§¤¤¥¡©Î¥ª°¼¡A¦Ü©ó¦b¦h±ø«aª¬°Ê¯ß¯f±wªÌ¡A¨ä²§±`¹q¦ì¤À§G¬O¦U³æ±ø«aª¬°Ê¯ß¯f¤§¹q¦ìªº²V¦X¡A²§±`­t¹q¦ì¤À§Gªº½d³ò¡A²§±`­t¹q¦ì«ùÄòªº®É¶¡¡A²§±`·¥¤p¹q¦ì«ùÄòªº®É¶¡»P«aª¬°Ê¯ß¯U¯¶ªºµ{«×¦³±K¤ÁªºÃö«Y¡C¦Ü©ó¨äÀ³¥Î©ó²§±`¤ß«Ç¾À¦¬ÁY¥ç¦³»ù­È[64]¡A²§±`ªº¦­´Á¤Ï¦V¹q¦ì¡]early reversal¡^»P¤£¥¿±`¤§¤ß«Ç¾À°Ê§@±K¤Á¬ÛÃö¡A¨£ªí9¡Bªí10¡A¤Îªí11¡C

¤»¡B ¤ß¾ÉºÞ³N¤§¬ÛÃö¬ã¨s
¡@ ¤ß¾ÉºÞ³N¡A¤×¨ä¬O¿ï¾Ü©Ê«aª¬°Ê¯ß³y¼v¡AÁ{§É¤W¹ï«aª¬°Ê¯ß©Ê¤ßŦ¯f¤§¶EÂ_¤Î³B²z¦³¨ä¦Ü¤µ©|µLªk³Q¨ú¥N¤§­«¤j»ù­È¡C¥x¤jÂå°|¦b1974¦~³ø§i[65,66]¦Û1973¦~°_¤§¦­´Á¸gÅç¦@24¨Ò¡A¥ÎSonesªkÀˬdªÌ22¨Ò¡A¨ä¦¨¥\²v¥k«aª¬°Ê¯ß³y¼v¬°95.4¢H¡A¥ª«aª¬°Ê¯ß¬°91¢H¡C¥t2¨Ò¥ÎJudkinsªkÀˬd³£¦¨¥\¡C21¨Ò«aª¬°Ê¯ß©Ê¤ßŦ¯f¤¤¡A¥H«e¤U¦æªK³Ì©ö¨ü¨ìªý¶ë©Ê¯fÅÜ«I¥Ç¡A¦@¦³90.5¢H¡A¦¸¬°¥k«aª¬°Ê¯ß57.1¢H¡A¦A¦¸¬°¥ª°j±ÛªK52.4¢H¡C³y¼v®É¤ß¹q¹Ï³£§e²{¤@®É©ÊST¤ÎTªiÅܤơA¥H¤Î¦UºØ§ÎºAªº¤ß«ß¤£¾ã¡C¤£¹L¡A¨S¦³¤@¨Ò¨Öµo¤ß«ÇÅÖºû©ÊŸ°Ê¡A¥ç¨S¦³¨ä¥L¤ßŦ¤è­±¤§¦X¨Ö¯gµo¥Í¡C§½³¡¦X¨Ö¯g¥u¦³¤@¨Ò (4.1¢H)¡A¨ä¥½µy°Ê¯ß¤§¯ß·i®ø¥¢¡A¤£¹L¨ÃµL¦Ûı¯gª¬µo¥Í¡C

ºaÁ`¦b1977¦~µoªí«aª¬°Ê¯ß¯f±wªÌ¤§¦åºÞ¯f²z¸Ñ­å¡B¦å¬y¤O¾Ç²§±`¤Î¤ß«Ç¦¬ÁY¤£¨ó½Õ¡]ventricular asynergy¡^¤§¬ÛÃö©Ê¬ã¨s[67]¡A¦b100­ÓºÃ¦ü«aª¬°Ê¯ß¯e¯f±wªÌ¤¤¦åºÞÄá¼v¦³«aª¬°Ê¯ß¯e¯fªº¸û¥¿±`¤Hªº¦å¬y¤O¾Ç²§±`¦³ÅãµÛ¤§¼W¥[¡A¨ä¥ª¤ß«Ç¥½´Á¤§À£¤O¸û°ª¡A¥ª¤ß«Ç¥½´Á¤§Åé¿n¸û¤j¡A¤ß¿é¥X¶q¸û§C¡A¦y®pdp/dt¤Î¦¬ÁY¦Ê¤À²v¸û§C¡C¤ß¹q¹Ï¤W¦³Qªi¤Î¯Ý³¡X¥ú¤ù¦³¤ßŦªÎ¤j¹ï«aª¬°Ê¯ß¯f¤H¤§¦å¦æ¤O¾Ç¦³¤£§Q¤§¼vÅT¡C¸Ó¤å¹ï¤ß«Ç¾À¦¬ÁY°ÊºA²§±`¤§¯f¤H§Q¥Îµv»Ä¥Ìªo¦Þ¤ù¤Î´Á¥~¦¬ÁY«á¥[±j§@¥Î¨Ó´ú©w¥ª¤ß«Ç¦¬ÁY¤£¨ó½Õ¤§¥i«ì´_©Ê¡A©ó§C¦¬ÁY¤§³¡¦ì¡BµL¦¬ÁY¤§³¡¦ì¹ï´Á¥~¦¬ÁY¤Îµv»Ä¥Ìªo¤§¤ÏÀ³¤À§O¬°40.7¢H¡B38¢H¤Î33.3¢H¡B25¢H¡C¦Ó²§±`¦¬ÁY¤§³¡¦ì«h§¡µL¤ÏÀ³¡C©ó§C¦¬ÁY²Õ¤§¯f¤H¤¤¡A¦³¯f²z©ÊQªiªÌ¸ûµLQªiªÌ¤ÏÀ³ÅãµÛ´î¤Ö¡]31¢H¤ñ80¢H¡^¡CµL¦¬ÁY¤Î²§±`¦¬ÁY¤§¯f¤H¥þ³¡§¡¦³¯f²z©Ê¤§Qªi¡C

¥x¤jÂå°|©ó1978¦~µoªí¥H¦åºÞÄá¼vµû¦ô«aª¬°Ê¯ß¤ßŦ¯f¤§¥ª¤ß¥\¯à[68]¡C¬ã¨sÅã¥Ü¯U¤ß¯g¯fªÌ¡A¤£½×¨ä¯Ýµh¤§¯S¼x¬°Ã­©w«¬¡]²Ä¢º«¬¡ã¢¼¯Å¡^©Î¬°¤£Ã­©w«¬¡A¨ä¤ß¥\¯à¬Ò¬°¥¿±`©Îªñ¥G¥¿±`­È¡C¤@¥¹µo¥Í¤ß¦Ù±ð¶ë¡]§Y¤ß¹q¹Ï¤W§e²{²§±`Qªi¡^¡A«h¤ß¥\¯à©¹©¹Âà¦H¡]P<0.001¡^¡A¤×¥H«e¾À±ð¶ë®É¥ª¤ß«Ç¤§·l¶Ëµ{«×»·¸û«á¾À±ð¶ë¬°ÄY­«¡]P<0.05¡^¡CX¥ú¤ù¤W¥X²{¤ßÂX¤j©ÎÁ{§É¼x­Ô¤W§e²{¤ß¤O°IºÜ®É¡A¨ä¤ß¥\¯à§ó¥[Âà¦H¡C¤ß¥\¯à¤§Àu¦H¡A¥D­n¨ú¨M©ó¥ª¤ß«Ç¦¬ÁY¹Ï¼Ë¤§²§±`»P§_¡C¤ß«Ç§eµL¦¬ÁY¹Ï¼Ë¡Aµo¥Í©ó¯U¤ß¯gªÌ¦@3¢H¡A¦Ó©ó¤ß¦Ù±ð¶ë¯gªÌ¡A°ª¹F71¢H¡]P<0.001¡^¡C«aª¬°Ê¯ßªý¶ë³¡¦ì¡Aµo¥Í©ó¥ª«aª¬°Ê¯ß«e¤U¦æªK®É¡A¨ä¦ñÀH§½³¡¤ß¾ÀµL¦¬ÁY¤§¾÷·|»·¸û¥k«aª¬°Ê¯ßªý¶ë®É¬°¤j¡C¦Ü©óªý¶ë¤§ÄY­««×©M¤ß¥\¯à¤§¶¡¨ÃµLª½±µ¤§Ãö«Y¡C¦U¶µ«ü¼Ð¢w¢w¥]¬A¥ª¤ßµÎ±i²×´ÁÀ£¤O¡BµÎ±i²×´Á®e¿n¡B¤ßÁY®g¥X¤À¶q¡]EF¡^¡B¼Ð·Ç¤Æ¤ßÁY¥­§¡®g¥X³t²v¡]Mean Normalized Systolic Ejection Rate, MNSER¡^¡B¶ê©Pª¬¦ÙÅÖºû¦¬ÁY¤§¥­§¡³t«×¡]Mean Velocity of Circumferential Fiber Shortening, Mean Vcf¡^¡B¥H¤Î¤ß¦¬ÁY³æ¤¸³Ì¤j¦¬ÁY³t«×¡]Maximal Velocity of Contractile Element Shortening, Vmax¡^µ¥¡A¥HEF¬°³ÌÀu¡A¦Ó¥HVmax³Ì®t¡C¨ä¥¦«ü¼Ð¤¤¥HMNSER»PEF¤§Ãö«Y³Ì±K¤Á¡]r¡×0.93¡AP<0.001¡^¡C

¦Ü©óÁ{§Éªí²{»P«aª¬°Ê¯ßÄá¼vªºÃö«Y¡A®Ú¾Ú¥x¤jÂå°|1978¦~ªº³ø§i¡A¥Ñ¨äµ±µhµ{«×¡Bµ±µh»¤µo¦]¯À¡A¤Î¤ß¹q¹Ï¤§Qªi¥i¹w¦ô¨äªý¶ë¯fÅܤ§±¡§Î¡CÀRºA¤ß¹q¹Ï¡A­YµLQªi¥X²{¡A¹ï«aª¬°Ê¯ß¯f¤§¦³µL¡AµLªk¹w¦ô¡A¥ç§Y¨äÁ{§É»ù­È¦³­­[69]¡C

¦Ü©ó«aª¬°Ê¯ß°¼ªK´`Àô¥\¯à¤W¤§·N¸q¡A¥x¤jÂå°|1985¦~³ø§i163¦W«aª¬°Ê¯ß¯f¤H¤§«aª¬°Ê¯ßÄá¼v¤Î¦å¦æ¤O¾Ç¸ê®ÆÅã¥Ü«aª¬°Ê¯ß°¼ªK´`ÀôÂA¤Ö¨£©ó¤p©ó90¢H¤§«aª¬°Ê¯ß¯U¯¶¡A¦b¥\¯à¤W«h¦³¯q©ó´î¤Ö¥ª¤ß«Ç¾À¹B°Ê¤§²§±`¤Î§ïµ½¦å¦æ¤O¾Ç¡AÁöµM¨ä«aª¬°Ê¯ß¯fÅܸûÄY­«[70]¡C°ê®õÂå°|©ó1992¦~µoªí[71]¸Ó°|1980¦~11¤ë¦Ü1991¦~2¤ë¶¡40¨Ò³æ¤@¥ª«e­°¤ä©Î¥k°¼«aª¬°Ê¯ßªý¶ë¤§¯f¨Ò¡A¤ÀªR¨ä«aª¬°Ê¯ß³y¼v¡B¥ª¤ß«Ç¹Ï¹³¡B¥H¤Î¤ß¹q¹ÏªºÅܤơAµo²{¨ã¦³¨¬°÷°¼ªK´`Àôªº¯f¤H¸û¤£¨¬ªÌ¦³¸û°ªªº¥ª¤ß«Ç®g¥X¤À²v¤Î¸û»´·Lªº§½³¡¥ª¤ß«Ç¾À¹B°Ê²§±`¡A¦ý¨ä¤ßµ±µh¯f¥v¡B¤ß¹q¹Ï²§±`Qªi«hµL®t²§¡C

佤©Ê¤ßŦ¯f¯f¤Hµo¥Í«aª¬°Ê¯ß¤ßŦ¯fªº¥i¯à©Ê±`¬O¬°¯f¤H°µ¤ß¾ÉºÞÀˬd®É«Ü¦³¿³½ìªº°ÝÃD¡C°¨°ºÂå°|¦b1991¦~³ø§i[72]¸Ó°|¦Û1985¦~1¤ë¦Ü1987¦~12¤ë¶¡175¦ì¤j©ó40·³ªºÃ¤½¤©Ê¤ßŦ¯f¯f±w¤§¤ß¾ÉºÞÀˬdµ²ªG¡Aµo²{19¦ì(11%)¦³«aª¬°Ê¯ß¤ßŦ¯f¡A¨ä¦~ÄÖ¸û¤j¡]64¡Ó9 vs.56¡Ó9·³¡^¡A¨ä¤¤8¦ì¦³°ª¦åÀ£¡B4¦ì¦³¿}§¿¯f¡B5¦ì¦³©â·Ï¡B8¦ì¦³¤ßµ±µh¡C¸Ó¤å§@ªÌ«ØÄ³¦~ÄÖ60·³¥H¤W¡B¦³¨å«¬¤ßµ±µh¡B¤Î¥D°Ê¯ß¹Ï¹³Åã¥Ü¦³«aª¬°Ê¯ß¯fªÌÀ³°µ«aª¬°Ê¯ßÄá¼v¡C

¤C¡B ®Ö¤l¤ßŦÂå¾Ç¤§¬ÛÃö¬ã¨s
¡@ ®Ö¤l¤ßŦÂå¾ÇÁ{§É¤WÀ³¥Î¤w¬Û·í´¶¹M¡A¦b«aª¬°Ê¯ß¯e¯fªºµû¦ô¤¤¤£¶È¥iºë½T´ú¶q¥ª¡B¥k¤ß«Ç¤§¦¬ÁY¥\¯à¡A¥ç¥i¥Î©ó¶EÂ_¤Î¦ô­p¯Ê¦å½d³ò¤§¤j¤p¡C

1981¦~¥x¤jµoªí¥H²Ä¤@¬ï¬y¦¡¦åºÞ°{Ã{Äá¼v³N¡]first passradionuclide angiocardiography¡^µû¦ô¥ª¤ß«Ç¥\¯à¡Aµo²{»PÅã¼v¤ß«Ç¹Ï¦³«Ü¦n¤§¬ÛÃö¡]r¡×0.90¡^¡C¥H¨äµû¦ô§½³¡¤ß«Ç¾À¥\¯à¤§·Ç½T«×§ó°ª¹F91¢H[73]¡C1985¦~¸Ó°|¥H§½³¡®g¥X¤À²v¼v¹³¡]regionalejection fraction image, REFI¡^¤Î²§±`¼v¹³¡]paradox image¡^¨Ó¶EÂ_¥ª¤ß«Ç½F¡Aµo²{REFI¥i¥¿½T°»´ú95¢Hªº¥ª¤ß«Ç½F¦Ó°²¶§©Ê²v¶È¬°5¢H¡C¦Ó²§±`¼v¹³«h¥i¥¿½T°»´ú87¢H¤£°Êªº¤ß«Ç½F¥BµL°²¶§©Ê[74]¡C°ê¨¾Âå¾Ç°|1986¦~µoªí¥H²Ä¤@¬ï¬y¦¡©M§¡¤Ã¦¡¤ßŦ¦åºÞ°{Ã{Äá¼v³N©ÒÀò±o¤§¬Û¦ì¹Ï§@©w¶q¤ÀªR¡A¥Hµû¦ô°Ï°ì©Ê¥ª¤ß«Ç¾À¤§¬¡°Ê¤O¡A¥çÃҹꬰ¤@¥i¾aªº¶EÂ_¤u¨ã[75]¡C

¦Ü©ó¥H¹B°Ê¦¡®Ö¤l¦åºÞ¤ßŦÅã¼v³N¶EÂ_«aª¬°Ê¯ß¤ßŦ¯f¡A¨ä¶EÂ_¨Ì¾Ú¬°úų̤j¹B°Ê¶q¤ULVEF¤§¤Wª@¤p©ó5¢H¡A©ÎúƳ̤j¹B°Ê¶q¤U¥X²{·sªº§½³¡¤ß¾À¹B°Ê²§±`¡C1986¦~¥x¤jµoªíªº¬ã¨sÅã¥Ü¨ä¶EÂ_ÆF±Ó«×°ª©ó¤@¯ë¹B°Ê¤ß¹q¹Ï¸ÕÅç¡]82¢H vs. 54¢H¡^¡A¦ý¯S²§«×¬Û¦P¡]72¢H¡^¡C¨Ï¥Î¤A«¬ªýÂ_¾¯ªÌ¶EÂ_ÆF±Ó«×·|­°§C¡]72¢H vs. 95¢H¡^[76]¡C

«aª¬°Ê¯ß¯f¥ª¤ß«Ç¦¬ÁY¥\¯à»PDipyridamole Thallium SPECT(thallium-201 single photon emission computed tomography)¤§¦A¤À§G(redistribution)«¬ºA¥ç¦³¬ÛÃö¡A¥x¤jÂå°|1992¦~µoªí31¨Ò¤§¬ã¨sµo²{¦p¦³¦A¤À§GªÌ¨ä¥ª¤ß¦¬ÁY¥\¯à¸û¨Î[77]¡C

¤K¡B ¨ä¥¦¤§¬ÛÃö¬ã¨s
¡@ ¢°¡D«aª¬°Ê¯ß¯f»P¥k¤ß«Ç¥\¯à
ºa¥ÁÁ`Âå°|©ó1982¦~³ø§i17¦W±µ¨ü§¹¾ãªº¤ß¾ÉºÞÀˬdªº¯f±w¡A¨ä¤¤²Ä¤@²Õ6¦WµL«aª¬°Ê¯ß¯fªÌ¬°¹ï·Ó²Õ¡A²Ä¤G²Õ¬°4¦WµL¥k«aª¬°Ê¯ß¯U¯¶¤§«aª¬°Ê¯ß¯fªÌ¡A²Ä¤T²Õ¬°7¦W¦³¥k«aª¬°Ê¯ß¯fªÌ¡C¬ã¨sµ²ªGÅã¥Ü¥k«aª¬°Ê¯ß¯U¯¶¹ï¥k¤ß«Ç¤ßÁY®g¥X¤À¶q¨ÃµL¼vÅT¡A¹ï¤ñ¾¯³æ­±¤ß«Ç¹q¼vÅã¼v³N©Ò´ú±oªº¥k¤ß«Ç¤ßÁY®g¥X¤À¶q¤§·Ç½T©Ê¥i»P©ñ®g©Ê¦P¦ì¯À¤ß«ÇÅã¼v³N¬Û¤ñ¡C¦ý¤T²Õ¯f¤Hªº¥k¤ß«Ç¤ßÁY®g¥X¤À¶q¨ÃµL©úÅã®t²§[78]¡C

¥x¤jÂå°|©ó1983¦~³ø§i117¦W¯fªÌ¤§¬ã¨s¡A¨C¤@¦W¬Ò¬I¥H²Ä¤@´`Àô©ñ®g©Ê®Ö¤l¤ßŦÅã¼v³NÀˬd¥H´ú©w¥ª¥k¤ß«Ç®g¥X¤À¶q¡C¨ä¤¤¦³62¦W±µ¨ü¤ß¾ÉºÞÀˬd¡Cµ²ªGÅã¥Ü¥¿±`¤H¤§¥k¤ß«Ç®g¥X¤À¶q¥­§¡­È¬°0.54¡Ó0.06¡A¤ñ¥ª¤ß«Ç®g¥X¤À¶q¤§0.65¡Ó0.06¬°§C(P<0.001)¡C¥k¤ß«Ç¥\¯à¤§¨}¦H¨ú¨M©ó¤ß¦Ù±ð¶ë¤§³¡¦ì¦Ó»P«aª¬°Ê¯ßªý¶ë¤§³¡¦ì¤Îµ{«×µLª½±µÃöÁp©Ê¡C«æ©Ê¤U¾À±ð¶ë¦ñµo¥k¤ß«Ç±ð¶ë®É¡A¥k¤ß«Ç¥\¯àÅãµÛ¤£¨}¡]¥k¤ß«Ç®g¥X¤À¶q¶È¬°0.35¡Ó0.10¡^[79]¡C

¢±¡D¯Ê¦å©Ê¤ßŦ¯f¯f±w¤§¤ß¦Ù¨Å»Ä¥NÁÂ[80]
¥x¤jÂå°|1977¦~µoªí¹ï35¦ìÃhºÃ¦³¯Ê¦å©Ê¤ßŦ¯fªº¯f±w¤§¤ß¦Ù¨Å»Ä¥NÁ ¬ã¨s¡C¯f¤H¦b¶i¦æ¶EÂ_©Ê¤ß¾ÉºÞÀˬd®É¥Ñ«aª¬ÀR¯ßÄu¤Î¥D°Ê¯ß¦P®É©â¦å§@¨Å»Ä´ú©w¡C¨ä¤¤¦³5¦ì¯f¤H¨Ã±µ¨ü¥k¤ß©Ð¹q®ð¿E·i¡A¥H¬ã¨s¤ß¦Ù­t²ü¼W¥[®É¨Å»Ä¥NÁªº¤ÏÀ³±¡§Î¡C30¦ì¥¼±µ¨ü¤ß©Ð¿E·iªº¯f¤H¤¤¦³25¦ì¨ä¨Å»ÄÄá¨ú²v¶W¹L10¢H¡A¬°¥¿±`¡A¨ä«aª¬°Ê¯ßªºÅܤƱ¡§Î©¼¦¹®t²§«Ü¤j¡C¥t5¦ì¤ß¦Ù¨Å»Ä¥NÁ²§±`ªº¯f¤H¤¤¦³3¦ì¬°¨k©Ê¡A¨ä¨Å»ÄÄá¨ú²v¤À§O¬° -6¢H¡B-26¢H¡B¤Î -35¢H¡A¬Ò¬°¤T±ø«aª¬°Ê¯ß¼F®`¯U¯¶¡F¥t2¦ì¤k©Ê¨ä­È¬° 0¢H¤Î¡Ï4¢H¡A¨ä¤¤1¤H«aª¬°Ê¯ß¥¿±`¡A¥t1¤H¶È¦³»´»´«×¤£³W«h¡A¥iµø¬°Syndrome¡Ñ¡C±µ¨ü¤ß©Ð¿E·iªº5¤H¤¤¶È¤@¤H¦³¨å«¬¯U¤ß¯g¡A¬°¤T±ø«aª¬°Ê¯ß¯e¯f¡A¦b¤ß©Ð¿E·i¶}©l«e¨ä¨Å»ÄÄá¨ú²v¬°¥¿±`(+28¢H)¡A¦ý¦b¿E·i4¤ÀÄÁ®ÉÅܬ°¨Å»Ä¥Í¦¨(-14¢H)¡A¦Ó¦b¿EáÞ¹F8¤ÀÄÁ¥H¤Î¿E·i«á4¤ÀÄÁ¤S³£«ì´_¥¿±`¡C¦¹ºØ±¡§Î§@ªÌ»{¬°¥i¯à¬O¤@ºØ¾AÀ³²{¶H¡A§Y¤p°¼ªK´`Àôªº©µ¿ð©ÊÂX±i¡C

¢²¡D¯Ê¦å©Ê¤ßŦ¯f¤§¤ßÁY®É¬q»P¦UºØ«Iŧ©Ê¤ß¥\¯à­p¶q¤§¬ÛÃöÃö«Y[81]
¥x¤jÂå°|1977¦~µoªí74¦W¸g«aª¬°Ê¯ßÄá¼v³NÃҹꬰ¯Ê¦å©Ê¤ßŦ¯fªÌ¡A§Q¥Î«D«Iŧ©ÊÀˬdªk¥]¬A¤ß¹q¹Ï¡B¤ß­µ¹Ï¤ÎÀV°Ê¯ßªi¹Ï¤§¦P®É°O¿ý¦Ó´ú±o¤§¦UºØ¤ßÁY®É¬q¢w¤×¥H¥ª¤ß«Ç®g¥X®É¶¡(Left ventricula rejection time ,LVET)¡A¥~°¼¦P¿n¤ßÁY®É¶¡(External isovolumic contraction time, EICT)¡A¤Î¤GªÌ¤§¤ñ(LVET/EICT)¡A±´°Q¦¹µ¥»P§Q¥Î«Iŧ©Ê¤ß¾ÉºÞÀˬdªk¦Ó´ú±o¤§¦UºØ¤ß¥\¯à¼Æ¾Ú¢w¢w¦p¤ßÁY®g¥X¤À¶q(Ejection fraction)¡A¤ßÁY±Æ¦å¶q¡A¥ª¤ß«Ç¤ßÁY²×´Á®e¶q¡A¤ßµÎ²×´Á®e¶q¥H¤Î¤ßµÎ²×´ÁÀ£¤Oµ¥¤§¶¡¤§Ãö«Y¡Cµ²ªGµo²{§Q¥Î«D«Iŧ©ÊÀˬd¦Ó±o¤§¦UºØ¤ßÁY®É¬q¼Æ¾Ú¡A¤×¥HLVET/EICT¤ñ­È¡A©M¥Ñ«Iŧ©ÊÀˬd¦Ó±o¤§¤ßÁY®g¤À¶q¤§ÃöÁp©Ê·¥¤j¡CÁ{§É¤W¹ï©ó¯Ê¦å©Ê¤ßŦ¯fªÌ¤§«aª¬°Ê¯ßªý¶ëµ{«×©Î¨ä¥ª¤ß¦¬ÁY¹Ï¼Ëµ¥¤ß¥\¯à¤§¹w¦ô¡A¤ßÁY®É¬q¤§´ú©w¦³¨ä»ù­È¡C

¢³¡D«aª¬°Ê¯ß¯f±wªÌ¤§¹¬´U¿ì²æ««»P³¬Âꤣ¥þ[82]
¥x¤jÂå°|¦b1978¦~³ø§i185¨Ò«aª¬°Ê¯ß¯f±wªÌ¤§¹¬´U䲿««¤Î³¬Âꤣ¥þ»P¨ä«aª¬°Ê¯ß¯fÅܪºÃöÁp¡Cµo²{¹¬´U䲿««¤Î³¬Âꤣ¥þ¤§¤ñ²v¤À§O¬°24.3¢H¤Î11.4¢H¡A¨âªÌ¬Ò¦³ªº¬°3.2¢H¡A¥BÀHµÛ¯fÅÜ«aª¬°Ê¯ß¼Æ¤§¼W¥[¦Ó¼W¥[¡A¦ý²Î­p¤W¥¼¹F¦³·N¸q¤§µ{«×¡C©Ò¦³45¦ì¹¬´U䲿««ªº¬Ò¬°«á¸­¡A¨ä¤¤¦³6¦ì¤ßŦ¶W­µªi¨ÃµL¹¬´U䲿««ªºÃÒ¨ã¡C³¬Âꤣ¥þªº¯f¤H¸û²æ««ªÌ¦³ÅãµÛ¸û¦hªº¥ª¤ß«Ç¦¬ÁY¤£¨ó½Õ(asynergy)(71.4¢Hvs 37.8¢H)¡A¤Î¤ß¦Ù±ð¶ë¯f¥v(p<0.005)¡C

¡@ TOP

¹w«á¤Î¤º¬ìªvÀø
¤@¡B ¹w«á¤è­±
¡@ °¨°ºÂå°|¦b1985¦~µoªí«D«Iŧ©Êµû¦ô«æ©Ê¤ß¦Ù±ð¶ë¯f¤H¦í°|¦º¤`²v¡A¦@¦³302¨Ò«æ©Ê¤ß¦Ù±ð¶ë¯f¤H¡A¨k©Ê223¨Ò¡A¤k©Ê79¨Ò¡Aµ²ªGµo²{(1)¯fµo«e¦³Ãö¦]¯À¦p¯Ê¦å©Ê¤ßŦ¯f¥v¡B°ª¦åÀ£¡B§l·Ï©M¿}§¿¯fµ¥¡A¨ã¦³¨âºØ¥H¤WªÌ¡A¨ä¹w«á¸û®t¡A§Y¸û°ª¦í°|¦º¤`²v¡C(2)¯fµo®É¦³Ãö¦]¯À¦p¦~ÄÖ¡]¯S§O¬O¶W¹L70·³¡^¡A¥Õ¦å²y¹L¦h(¡Ù10,000/pmm)¡A¦å¿}¹L°ª(¡Ù140mg/dl)¡AÄY­«¤ß«ß¤£¾ã¡A±ð¶ë³¡¦ì¡]¼sªx«e¾À¡^¤Î¥ª¤ß«Ç¥\¯à´î·l¡]Killip¤ó¤ÀÃþ¤¤¸û°ªµ¥¯Å¡^µ¥¡A¨ã¦³³o¨Ç¦]¯À·|©úÅã´£°ª¦º¤`²v[83]¡C¥x¤jÂå°|¦b1970¦~µoªí¦Û¥Á°ê49¦~¨ì57¦~¶¡¦]«æ©Ê¤ß¦Ù±ð¶ë¦í°|¤§¯f¤H¦@347¤H¡A²Î­p¨ä¦í°|«á¨â­Ó¤ë¤º¤§¦º¤`²v¡]ªñ±µ¦º¤`²v¡^¡A¥H¤Î¦Û¥Á°ê49¦~¨ì53¦~¶¡¤§«æ©Ê¤ß¦Ù±ð¶ë¯g67¯f¨Ò¥H¤ÀªR²Î­p¨ä¤­¦~¶¡¤§¦º¤`²v¡Cµ²ªGµo²{«æ©Ê¤ß¦Ù±ð¶ëµo¯f«á¨â­Ó¤ë¤º¦º¤`ªÌ¦û19.6¢H¡A¨ä¤¤¤k©Ê¦º¤`°ª©ó¨k©Ê¡A¥D­n¦º¤`¤§­ì¦]¥H¤ßŦ°IºÜ©Î¤ß¦]©Ê¥ð§J¬°¥D¡A¬ðµM¦º¤`¦ûÁ`¦º¤`¤§33.8¢H¡C¥X°|«á5¦~¶¡¤§¦º¤`²v¬°28.4¢H¡A¤j³¡¤À¦º¤`µo¥Í©ó¥X°|«á3¦~¤º¡A¥D­n¦º¤`­ì¦]¬°¤ßŦ¦åºÞ¯e¯f¡A¤×¥H¤ß¦Ù±ð¶ë¤§´_µo¬°³Ì[84]¡C
¤G¡B ¤º¬ìªvÀø¤è­±
¡@ ¤T­xÁ`Âå°|¦b1980¦~µoªíacebutolol»Ppropranolol¤Î¦w¼¢¾¯¹ï¤ßµ±µh±wªÌ¤§Àø®Ä¤Î¹B°Ê­@©Ê¤§¤ñ¸û¬ã¨s¡Aµo²{¨âºØ¤A«¬ªýÂ_¾¯¹ï©ó´î¤Ö¯f±w¤ßµ±µhµo§@¦¸¼Æ¤Îµv»Ä¥ÌªoªA¥ÎÁû¼Æ¨ã¦³¬Û¦P®ÄªG¡C¨âªÌ¬Ò¯à¼W¥[¯f±w¹B°Ê®É¶¡¡A´î¤Ö¤ß¹q¹ÏST-Tªi¤U­°®æ¼Æ¡A´î¤ÖÀR¤î®É¤ß¸õ¦¸¼Æ¤Î¤T­«²£ª«¡]¤ß¸õ¡Ñ¥­§¡¦åÀ£¡Ñ¥ª¤ß«Ç®g¦å®É¶¡¡^¡A´î¤Ö¹B°Ê®É³Ì¤j¤ß¸õ¦¸¼Æ¤ÎÂù­«²£ª«¡]¤ß¸õ¡Ñ¥­§¡¦åÀ£¡^¡CPropranolol´î¤ÖÀR¤î¤ß¸õ¦¸¼Æ¡A¹B°Ê³Ì¤j¤ß¸õ¦¸¼Æ¤ÎÀR¤î¤T­«²£ª«¸ûacebutololÅãµÛ[85]¡C¸Ó°|©ó1985¦~µoªí¥t¤@Ãþ¦üªº¬ã¨s¡A¥H¼i±a¦¡¹B°Ê¤ß¹q¹Ï¸ÕÅç¤ñ¸ûcarteolol 5mg bid©Mpropranolol 40mg bid¹ï©óºC©Ê¦w©w©Ê¤ßµ±µh¯f±wªÌ¤§¥\®Ä¡Aµo²{¨âªÌ¤§§Ü¤ßµ±µh©M¹B°Ê¥\®Ä¬Û¦ü¡A¦ýpropranolol¯à´î¤ÖÀR¤î¤ß¸õ¦¸¼Æ©MÂù­«²£ª«¦Ócarteolol«oµLÅãµÛ§ïÅÜ[86]¡C

¦Ü©ó«æ©Ê¤ß¦Ù±ð¶ë¤§¦å®ê·»¸ÑÀøªk¦b°ê¤º¦­¤w¦æ¤§¦h¦~¡A¦ý¥¿¦¡¤§¤åÄm³ø§iµ§ªÌ¶È¦¬¶°¨ì¤@½g¡A¬OºaÁ`1985¦~©Òµoªí11¨Ò«æ©Ê¤ß¦Ù±ð¶ë¤§¯f±w©ó6¤p®É¤º±µ¨üÃì²yµß¿Eþù150¸U³æ¦ì¡A§¡µL­«¤jªº°Æ§@¥Î¡CªvÀø¤§±wªÌ¡A¨Ï¥Î¥Ì¤óÁ{§É¶¡±µ¤èªkµû¦ô¡A11¨Ò¤§¤¤¦³9¨Ò¯à¨Ï¦å¬y¦AºZ³q¡A³qºZ²v¹F82¢H¡F±wªÌ¤¤¦³9¨Ò¦b2¶g¤º¶i¦æ¤ß¾ÉºÞÀˬd¡A¨ä¤¤7¨Ò¯A¤Îªý¶ë¤§«aª¬°Ê¯ß§¡¯à³qºZ¡A¨ä³qºZ²v¬°78¢H¡C¦b¹ï·Ó²Õ¤§¤¤¦@¦³10¦ì¯f¤H¡A¦b±ð¶ë«á3¶g¥ª¥k¶i¦æ¤ß¾ÉºÞÀˬd¡A¶È¦³3¦ì³qºZ¡A¨ä³qºZ²v¶È¦³30¢H¡C¥i¨£¤j¶qÀR¯ßª`®gÃì²yµß¿E¡A¨ã¨}¦n¤§ªvÀø»ù­È[87]¡C

«aª¬°Ê¯ßÂX±i³N¦b°ê¤º¥ç¦­¤w¦³¦h®aÂå°|¦³¬Û·íÂ×´IªºÁ{§É¸gÅç¡A¦ýµÛ¦¨½×¤åªº¥ç¤Ö¡CºaÁ`©ó1984¦~³ø§i11¨Ò¥ª«e­°ªK°Ê¯ßÂX±i³N¡A¦p¥H³N«á¯U¯¶´î¤Ö¦Ê¤À¤§¤G¤Q¡B©Î¯U¯¶¤§À£¤O®t´î20Íù¦Ì¤ô»È¬W¥H¤WªÌµø¬°¦¨¥\¡A«h¨ä¤¤¦³8¦ì¦¨¥\¡A¦¨¥\²v¬°73¢H¡C¯Ýµh¤§¯gª¬¡A¹B°Êªº­@¶q¡A¤ßŦ·i¥X²v¡A¥H¤Î¤ß¦Ù¦P¦ì¯À°{Ã{·Ó¬Ûµ¥Àˬd¡A¦bÂX±i¤§«á§¡¦³©úÅ㤧¶i¨B[88]¡C

ºaÁ`©ó1991¦~µoªí[89]«æ©Ê¤ß¦Ù±ð¶ë¦å®ê·»¸Ñ¾¯ªvÀøªk¤§«aª¬°Ê¯ßÂX±i³N¤§¬ã¨s¡A31¦ì©ó¯Ýµh5¤p®É¤º¨ì¹FÂå°|¨Ã±µ¨ü²Õ´­M¼ß­ì¬¡¤Æ¾¯(rt-PA)100mg ª`®g¤§«æ©Ê¤ß¦Ù±ð¶ë¤§±wªÌ°£¤@¨Ò¦º¤`ªÌ¥~¡A¨ä¾l¬Ò©ó²Ä¤T¤p®É§¹¦¨ª`®g®É¶i¦æ«aª¬°Ê¯ßÄá¼v¡A¨ä¤¤25¨Ò(83¢H)¤§±ð¶ë¦³Ãö°Ê¯ß³qºZ¡C¤§«áÀH¾÷¤À¬°¤G²Õ¡A¥Ò²Õ¦b¨â¤Ñ¤º¶i¦æ«aª¬°Ê¯ßÂX±i³N¡A¤A²Õ«h¦b¤T¶g¤§«á°µ¡Cµ²ªG¥Ò²Õ¤§±wªÌ¦³16¦ì¡A¨ä¤¤14¦ì±µ¨ü«aª¬°Ê¯ßÂX±i³N¡A11¦ì(78.6¢H)¦¨¥\¡C¤A²Õ14¦ì±wªÌ¤¤9¦ì±µ¨ü«aª¬°Ê¯ßÂX±i³N¡A7¦ì(78¢H)¦¨¥\¡C±wªÌ¤§¦í°|¦º¤`²v¬°9.6¢H¡A»P¤â³N¤§¦­±ßµLÃö¡C

¡@ TOP

°Ñ¦Ò¤åÄm
1¡D ³¯¬³©ú¡A³s¤å±l¡G¥xÆW¤§¤ßŦ¦åºÞ¨t¯e±w¡D¥xÆWÂå»x¡A1963;256-72.
2¡D HC Tsai, WP Tseng, et al.: Coronary heart disease and hypertension in Taiwan aborigines. Am J Epidemiol, 1967; 86 : 253-63.
3¡D YZ Tseng, WP Tseng, CM Chen: Electrocardiographic findings in Chinese urban population. J Formosan Med Assoc. 1974; 73: 89-104.
4¡D YB Li, RA Bruce, N Ting, CL Yang: Incidence and risk factors of coronary heart disease and cerebral vascular accident in Chinese men: A remarkable low prevalence of risk factors for coronary heart disease. Chin J Cardiol 1981; 1: 143-55.
5¡D YT Lee, JJ Tjung, et al.: Young patients with acute myocardial infarction in Taiwan -- a study on chinical manifestations, risk factors, angiographic characteristics and outcome. Chin J Cardiol 1981; 1 : 156-68.
6¡D ½²¿üµ^¡A§d«T­«¡A³¯·ç¤T¡G«aª¬°Ê¯ßµw¤Æ©Ê¤ßŦ¯f¯f¤H¤§Áx¾J¶q¡D¥xÆWÂå»x¡A1962; 61: 1031-8.
7¡D §d«T­«¡A²ø­õ«Û¡A§õ·½¼w¡A½²¿üµ^¡G¤ß¦Ù±ð¶ë¤Î«aª¬°Ê¯ßµw¤Æ©Ê¤ßŦ¯f¯f¤H¤§¯×¦å¼á²M¾÷¯à¡D¥xÆWÂå»x¡A1972; 71: 54-9.
8¡D PJ Huang, JS Chen, et al: lipid abnormality in Chinese with angiographically proved coronary artery disease. J Formosan Med Assoc. 1977; 76: 612-20.
9¡D YA Ding, D Chen, YB Li.: Lipid abnormalities of atherosclerotic diseases in Chinese men. J Formosan Med Assoc. 1982; 81: 559-67.
10¡D YA Ding, D Chen, YB Li: Lipid abnormalities in Chinese patients with coronary heart disease. Chin Med J 1982; 29: 153-60.
11¡D ML Sung, TY Tsai, et al.: Apoprotein B: a discriminator of coronary heart disease. J Formosan Med Assoc. 1986; 85: 368-75.
12¡D BN Chiang, N Ting, et al.: Physical characteristics and exercise performance of pedicab and upper socioeconomic classes of middle-aged Chinese men. Am Heart J 1968; 76: 760-8.
13¡D SH Tsai: Clinical studies on cardiovascular diseases of diabetes in Taiwan. J Formosan Med Assoc. 1963; 62: 1-12.
14¡D ¶ÀÄ£¬P¡G²§«¬¯U¤ß¯g¡G³ø§i¤@¨Ò¡D¥xÆWÂå»x¡A1974; 73 : 466-70.
15¡D BN Chiang, MS Chang, SP Wang: Coronary artery spasm documentation by selective cine coronary arteriography. Chin J Radiol. 1977; 2: 31-40.
16¡D CZ Liu, KM Jan, et al.: Prinzmetal's variant form of angina pectoris: a case detected by continuous Holter monitoring. J Formosan Med Assoc. 1985; 84; 117-26.
17¡D PJ Huang, YT Lee, et al.: Unstable angina pectoris: arteriographic, hemodynamic and therapeutic experience in 64 patients. J Formosan Med Assoc. 1978; 77 (11): 815-24.
18¡D HC Tsai, TS Yen, et al.: Clinical observation on myocardial infarction in 1954-1959 hospital material. J Formosan Med Assoc. 1960; 59 : 608-20.
19¡D JH Chen, SY Bair, et al.: The hospital course of acute myocardial infarction in the Tainan Area. J Formosan Med Assoc. 1991; 90: 127-31.
20¡D Sheng-Chuan Hu: A Study on the pre-admission characteristics of patients with acute myocardial infarction. J Formosan Med Assoc 1991; 90: 460-4.
21¡D Chiau-Suong Liau, Liang-Cheng Hahn, Jin-Jin Tjung, et al.: The clinical characteristics of acute myocardial infarction in aged patients. J Formosan Med Assoc 1991; 90: 122-6.
22¡D HC Tsai, YT Lee: A study of high anterior chest leads for the diagnosis of the high anterolateral myocardial infarction. J Formosan Med Assoc. 1972; 71 : 1-12.
23¡D TL Wu, HC Tsai: The electrocardiographic diagnosis in posterobasal myocardial infarction. J Formosan Med Assoc. 1975; 74: 86-102.
24¡D JS Chen, HC Tsai, TL Wu: Clinical observation on transaminase activity. J Formosan Med Assoc. 1962; 61: 707-13.
25¡D YS Lee, WP Lien, et al.: Cardiac enzyme study in the diagnosis of acute myocardial infarction -- simultaneous determinations of creatine phosphokinase isoenzymes and lactate dehydrogcnase isoenzymes. J Formosan Med Assoc. 1977; 76: 604-11.
26¡D CS Lin, MC Shih: Reappraisal of enzyme diagnosis in acute myocardial infarction. J Formosan Med Assoc. 1979; 78: 789-94.
27¡D HS Luo, SC Lin, TC Wang, HC Chiu: Predominant right vertricular infarction. J Formosan Med Assoc. 1979, 78: 840-1.
28¡D ¸­´Ë¬w¡A³\¤l¨q¡AÁ¤åÙyµ¥¡G¥k¤ß«Ç¤ß¦Ù±ð¶ë¯g¡D¥xÆWÂå»x¡A1982; 81: 507-13.
29¡D SC Yang, YT Lee, et al.: Bedside dagnosis of ventricular septal defect complicating acute myocardial infarction. J Formosan Med Assoc. 1977; 76: 579-85.
30¡D YT Lee, PJ Huang, et al.: Experience on postinfarction ventricular septal defect. Chin J Cardiol 1981; 1 :53-61.31.~|DF Lee, PJ Huang, et al.: Post infarction ventricular septal rupture. J Formosan Med Assoc. 1983; 82: 609-17.
31¡D YY Hsieh, HC Tsai: Conduction disturbances in acute myocardial infarction. J Formosan Med Assoc. 1972; 71 : 203-13.
32¡D ³\³Ó¶¯¡G«æ©Ê¤ß¦Ù±ð¶ë¦X¨Ö§¹¥þ©Ð«Ç¶Ç¾Éªýº¢¡D¥xÆWÂå»x¡A1979; 78: 276-81.
33¡D TL Wu: Hemiblock in acute myocardial infarction. J Formosan Med Assoc.1977; 76: 461-71.
34¡D SJ Yeh, FC Lin, JS Hung, Delon Wu: Significance of bundle branch or fascicular block complicating acute myocardial infarction. J Formosan Med Assoc. 1982; 81: 1543-51.
35¡D YB Li, SS Lee: Heart sounds and cardiac movement in acute myocardial infarction. Chinese M.J. 1971; 18: 52-8.
36¡D CY Wen, PJ Huang: Postinfarction ventricular aneurysm: Clinical and hemodynamic aspects. J Formosan Med Assoc. 1978; 77: 640-8.
37¡D CS Liau, YT Lee, PJ Huang, et al.: Normalization of electrocardiogram after myocardial infarction. -- a hemodynamic and angiographic study. J Formosan Med Assoc. 1983; 82: 245-58.
38¡D MF Chen, YT Lee: Coronary arteriographic findings after myocardial infarction. J Formosan Med Assoc. 1986; 85: 1117-27.
39¡D Jiunn-Yih Wu, Chung-Ze Liu, Paul Huai Chen, et al.: Arrythmias in patients with ventricular aneurysm after myocardial infarction. Acta Cardiol Sin 1991; 7: 180-7.
40¡D Kuen-Yan Tsai, Shih-Pu Wang, Fong-Yuh Tung, et al.: Cardiac arrythmias in patients treated for evolving myocardial infarction with recombinant tissue plasminogen activator. Acta Cardiol Sin 1991; 7: 68-76.
41¡D Chan-Ming Wu, Shoa-Lin, Tsui-Lieh Hsu, et al.: Serial analysis of echocardiographic gray levels in patients with acute myocardial infarction. Acta Cardilo Sin 1991; 7: 173-9.
42¡D CM Chen: Studies of tests on cardiovascular functions. Part ¢º. Reevaluation of the criteria for two-step exercise test. J Formosan Med Assoc. 1960; 59 : 524-33.
43¡D YT Lee, WP Tseng, YZ Tseng: Double Master two-step exercise testing in the Chinese. J Formosan Med Assoc. 1976; 75: 96-108.
44¡D PJ Huang, HC Chiu, YT Lee: Appraisal of the double Master's two-step test: correlation with coronary arteriographic findings. J Formosan Med Assoc. 1977; 76: 441-50.
45¡D BL Ho, DJ Wang, YT Lee: A study of differences in interpretation of exercise electrocardiogram. J Formosan Med Assoc. 1978; 77: 859-67.
46¡D YZ Tseng, CD Tseng, JS Chen: A correlation between test and abnormal resting electrocardiogram. Chin J Cardiol, 1981; 1 : 169-80.
47¡D BN Chiang, SS Lee, JY Mu, et al.: Maximal treadmill exercise stress testing in angiographically documented coronary artery disease in Chinese. Chinese M.J. 1977; 24: 115-26.
48¡D TS Hsu, CW Chiang, YS Lee, et al.: Experience of treadmill exercise testing in ischemic heart disease. J Formosan Med Assoc. 1981; 80: 740-50.
49¡D TS Hsu, CW Chiang, YS Lee, JS Hung: Treadmill exercise testing in patients with significant coronary artery disease. J Formosan Med Assoc. 1984; 83: 156-66.
50¡D BN Chiang, N Ting, ER Alexander, et al.: Maximal exercise responses in middle aged hypertensive and normotensive Chinese males: a preliminary report. Chinese M.J. 1967; 14 (13): 239-50.
51¡D YB Li, N Ting, BN Chiang, et al.: Electrocardiographic response to maximal exercise -- treadmill and double Master exercise tests in middle-aged Chinese men. Am. J Cardiol 1967; 20: 541-8.
52¡D RA Bruce, YL Pao, N Ting: Seven-year follow-up of cardiovascular study and maximal exercise of Chinese men. Circulation, 1975; 51: 890-900.
53¡D N Ting, YB Li, BN Chiang: Significance of maximal exercise ST responses in middle-aged Chinese men. Isr J Med Sci, 1969; 5 : 691-5.
54¡D PS Chen, YT Lee, SC Liau: Ventricular fibrillation induced by treadmill exercise testing -- a case report and a review of literatures. J Formosan Med Assoc. 1979; 78 : 141-9.
55¡D HT Chou, BN Chiang, SS Lee: Exertional ventricular fibrillation after maximal treadmill exercise stress testing. Chinese
Med J 1980; 27 : 524-9.
56¡D TS Hsu, CW Chiang, YS Lee, JS Hung: Measurement of R wave amplitude in treadmill exercise tests -- a simplifiedmethod and its clinical application. J Formosan Med Assoc. 1984; 83: 986-95.
57¡D YZ Tseng: Non-invasive diagnosis of ischemic heart disease. J Formosan Med Assoc. 1977; 76: 192-208.
58¡D YZ Tseng, WP Lien, CM Chen, TL Wu: Non-invasive diagnosis of ischemic heart disease Part¡E¢º. Vectorcardiographic criteria for positive exercise test. J Formosan Med Assoc. 1977; 76: 529-45.
59¡D YZ Tseng, PJ Huang, TL Wu: Evaluation of severity of ischemic heart disease by the resting vectorcardiogram. J Formosan Med Assoc. 1978; 77: 1-15.
60¡D YZ Tseng, TL Wu: Vectorcardiographic assessment of exercise tolerance in potients with ischemic heart disease. J Formosan Med Assoc. 1978; 77: 154-64.
61¡D YZ Tseng, CD Tseng, HM Lo, et al.: The response of the maximal QRS vector to exercise in patients with coronary artery disease. J Formosan Med Assoc. 1984; 83: 243-55.
62¡D YZ Tseng, CD Tseng, HM Lo, et al.: Clinical application of body surface potential mapping in patients with coronary artery disease. J Formosan Med Assoc. 1988; 87 : 514-24.
63¡D YZ Tseng, CD Tseng, HM Lo, et al.: The value of body surface potential maps in detecting abnormal ventricular wall motion. J of Electrocardiol 1990; 23 : 127-36.
64¡D ¶À³Õ¬L¡AªôùÚ¥¿¡AÁª¢³ó¡A³¯¬³©ú¡G«aª¬°Ê¯ßÄá¼v³N¢w24¨Ò¦­´Á¸gÅ礧³ø§i¡D¥xÆWÂå»x¡A1974; 73: 22-34.
65¡D ¶À³Õ¬L¡A³¯¬³©ú¡G«aª¬°Ê¯ßÄá¼v³N¡]¸Ñ­å¡B³y¼v¤Î¾AÀ³¤§µû¤¶¡^¡D¥xÆWÂå»x¡A1974; 73: 232-9.
66¡D BN Chiang, et al.: A correlative study on angiographic pathoanatomy, hemodynamic dysfunction and ventricular asynergy in patients with coronary artery disease. Chinese M.J. 1977; 24: 36-54.
67¡D PJ Huang: Assessment of left ventricular performance in coronary artery disease. J Formosan Med Assoc. 1978; 77: 16-34.
68¡D PJ Huang, YT Lee, et al.: Clinical and arteriographic correlations in cororary artery disease. J Formosan Med Assoc. 1978; 77 : 142-53.
69¡D CS Liau, YT Lee, MF Chen, TL Wu: Functional significance of coronary collateral circulation. J Formosan Med Assoc. 1985; 84: 188-97.
70¡D Zin-Gang Lin , Paul H. Chen , Ji-Huang Wang , et al.: The protective role of coronary collaterals in patients with single coronary artery occlusion. Acta Cardiol Sin 1992; 8: 22-8.
71¡D Chung-Huo Chen ,Paul H. Chen ,Huan-Cheng Chiou, et al. :The incidence of cororary artery disease in patients with valvular heart disease. Acta Cardiol Sin 1991; 7: 125-9.
72¡D PJ Huang, CC Chen, YT Lee, et al.: Assessment of left ventricular ejection fraction and regional wall motion from first pass radionuclide technique: contrast angiographic validation. Chinese J. Cardiol 1981; 1: 1-12.
73¡D PJ Huang, CT Su, YT Lee, TL Wu: Accuracy of first-pass regional ejection fraction image and paradox image in detecting left ventricular aneurysm. J Formosan Med Assoc. 1985; 84 : 354-62.
74¡D WL Chen, DJ Wang, FK Chang, PK Sung: Quantitative evaluation of regional left ventricular wall motion by phase image analysis. J Formosan Med Assoc. 1986; 85: 109-17.
75¡D PJ Huang, CT Su, YT Lee, et al.: Diagnosis of coronary artery disease by exercise radionuclide angiography. J Formosan Med Assoc. 1986; 85: 359-67.
76¡D Li-Jen Lin, Fu-Tien Chiang, Por-Jau Huang, et al. Correlation between left ventricular systolic function and dipyridamole thallium SPECT redistribution patterns in coronary artery disease. J Formosan Med Assoc 1992; 91: 46-51.
77¡D WL Chan, SS Lee, BN Chiang, et al: Coronary artery disease and right ventricular function. Chin Med J 1982; 29: 11-20.
78¡D PJ Huang, CT Su, YT Lee, et al: Right ventricular function in acute myocardial infarction and chronic coronary artery disease, J Formosan Med Assoc 1983; 82: 564-74.
79¡D CS Liou, PJ Huang, HC Chin, et al :Myocardial lactate metabolism in patients with ischemic heart, J.F.M.A 1977 76: 19-8.
80¡D TL Wu, PJ Huang, YZ Tseng, YT Lee.: Correlation between systolic time intervals and invasive direct measures of left ventricular performance in ischemic heart diseare. 1977; 76: 107-18.
81¡D CD Tseng, TY Lee, PJ Huang, TL Wu.: Mitral valve prolapse and mitral regurgitation in patients with coronary artery disease. 1978; 77: 649-58.
82¡D CH Tsa;, TC Wu, DF Lee , et al.: Noninvasive parameters influencing hospital mortality in patients with acute myocardial infarction 1985; 1: 243-52.
83¡D SL Kao: Prognosis of acute myocardial infarction in National Taiwan University Hospital, immediate and five-year fatality. J Formosan Med Assoc 1970; 69 (2): 83-8.
84¡D YA Ding, KK Chang, CC Lin, et al: A comparative study of acebutolol, propranolol and placebo on exercise tolerance in patients with angina pectoris. 1980; 27: 637-41.
85¡D ¼B¥AµØ¡A¿à¤å·½¡A³¯¼á¡@¡AÁ¤h©ú¡G carteolol »P propranolol ¹ïºC©Ê¦w©w©Ê¤ßµ±µh±wªÌ¹B°Ê¥\¯à¤§¤ñ¸û¬ã¨s¡D¥xÆWÂå»x¡A1985; 84: 457-61.
86¡D SP Wang, CY Chou, CW Pan, et al: The efficacy of intravenous Streptokinase therapy in acute myocardial infarction. 1985; 35: 234-41.
87¡D SP Wang, MS Chang, CW Pan, et al.: Percutaneous transluminal coronary angioplasty for single left anterior descending artery disease-initial VGH experience. Chin Med J 1984; 34: 527-36.
88¡D Shih-Pu Wang. Min-Ji Charng ,Chun-Peng Liu ,et al.: Percutaneous transluminal coronary angioplasty after thrombolytic therapy in acute myocardial infarction . Acta Cardiol Sin 1991; 7: 6-14.
¡@ TOP


¡@